eff Cancer Research Results
eff, efficacy: Click to Expand ⟱
| Source: |
| Type: |
Power to enhance an anti cancer effect
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Nor, |
HT29 |
|
|
|
- |
in-vivo, |
Nor, |
NA |
|
|
|
- |
in-vivo, |
IBD, |
NA |
|
|
|
*Inflam↓, 1,8-cineole treatment significantly decreased the inflammatory response in DSS-induced colitis mice.
*NRF2↑, 1,8-cineole treatment also increased nuclear factor erythroid 2-related factor 2 (Nrf2) translocation into the nucleus to induce potent antioxidant effects.
*antiOx↑,
*PPARγ↑, 1,8-cineole also increased colonic PPARγ protein expression.
eff↑, 1,8-cineole may be valuable in treating IBD
Glycolysis↓, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death
HK2↓,
mt-ROS↑, 2-DG-mediated glucose deprivation stimulates reactive oxygen species (ROS) production in mitochondria, also leading to AMPK activation and autophagy stimulation.
AMPK↑,
PPP↓, 2-DG has been shown to block the pentose phosphate shunt
NADPH↓, Decreased levels of NADPH correlate with reduced glutathione levels, one of the major cellular antioxidants.
GSH↓,
Bax:Bcl2↑, Valera et al. also observed that in bladder cancer cells, 2-DG treatment modulates the Bcl-2/Bax protein ratio, driving apoptosis induction
Apoptosis↑,
RadioS↑, 2-DG radiosensitization results from its effect on thiol metabolism
eff↓, (NAC) treatment, downregulated glutamate cysteine ligase activity, or overexpression of ROS scavenging enzymes
Half-Life↓, its plasma half-life was only 48 min [117]) make 2-DG a rather poor drug candidate
other↝, Adverse effects of 2-DG administration in humans include fatigue, sweating, dizziness, and nausea, mimicking the symptoms of hypoglycemia
eff↓, Moreover, 2-DG has to be used at relatively high concentrations (≥5 mmol/L) in order to compete with blood glucose
tumCV↓, ISO reduced the survival rate of gastric cancer AGS cells, but the toxicity to normal cells was minimal. Isoorientin Reduces the Viabilities of Gastric Cancer Cells
selectivity↑,
*toxicity↓,
Apoptosis↑, ISO induced apoptosis in gastric cancer AGS cells
ROS↑, level of reactive oxygen species (ROS) in gastric cancer AGS cells also increased with the extension of the ISO treatment time
eff↓, However, cell apoptosis was inhibited by preconditioning cells with N–acetylcysteine (NAC).
TumCCA↑, ISO arrested the cell cycle at the G2/M phase by increasing intracellular ROS levels.
p‑Akt↓, ISO inhibited cell migration by inhibiting the expression of p–AKT, p–GSK–3β, and β–catenin and was also related to the accumulation of ROS.
p‑GSK‐3β↓,
β-catenin/ZEB1↓,
TumCMig↓, Isoorientin Inhibited AGS Cell Migration via the AKT/GSK–3β/β–catenin Signaling Pathways
Twist↓, Twist, ZEB1, N–cadherin, and β–catenin were all decreased, while the expression levels of E-cadherin were increased
N-cadherin↑,
β-catenin/ZEB1↓,
E-cadherin↑,
| - |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-468 |
|
|
|
Glycolysis↓, Metabolomic analyses showed that 3BP causes inhibition of glycolysis
RadioS↑, Overall, MCT1-mediated metabolic perturbation in combination with radiotherapy is shown to be a promising strategy for the treatment of glycolytic tumors such as TNBC, overcoming the selectivity challenges of targeting glycolysis with glucose analogs
eff↑, 3BP is selectively toxic to cells expressing MCT1
GAPDH↓, 3BP inhibits GAPDH but not hexokinase
PPP↑, Pentose phosphate pathway is upregulated in response to 3BP
GSH↓, Glutathione and NADH are depleted at early time points
ECAR↓, prolonged incubation with 20 μM 3BP for 24 h resulted in a statistically significant selective decrease in ECAR
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
Caco-2 |
|
|
|
- |
in-vitro, |
CRC, |
SW48 |
|
|
|
ATP↓, 3-Bromopyruvate (3BP) is a pyruvate analogue with alkylating properties that depletes cellular ATP levels and induces rapid cell death in neoplastic cells with limited cytotoxic effects against normal cells.
TumCD↑,
selectivity↑,
toxicity↓, 3BP treatment led to eradication of tumours of hepatocellular carcinoma cell origin in rats without apparent cytotoxic effects [19]
OS↑, first human case report suggested that 3BP was able to prolong survival in a cancer patient diagnosed with hepatocellular carcinoma in 2012 [19,20].
HK2?, 3BP is able to dissociate and inhibit mitochondrial HKII function, thereby reducing ATP production. 3BP binding also frees up binding sites previously occupied by HKII
Cyt‑c↑, llowing pro-apoptotic molecules (such as BAX and BAD) to promote the release of cytochrome c into the cytosol and induce eventual cell death
eff↑, Raji lymphoma cells grown under hypoxic conditions were more sensitive to 3BP than in normoxia
p‑Akt↑, 3BP induces rapid AKT phosphorylation at residue Thr-308
eff↑, novel microencapsulated formulation of 3BP (ME3BP-7), which is effective against a variety of PDAC cells in vitro and remains stable in serum.
TumCG↓, Furthermore, systemically administered ME3BP-7 significantly reduces pancreatic cancer growth and metastatic spread in multiple orthotopic models of pancreatic cancer with manageable toxicity.
TumMeta↓,
toxicity↝,
Glycolysis↓, The anticancer effects of 3BP were initially attributed to inhibition of glycolysis (Ganapathy-Kanniappan et al., 2009;
toxicity↓, Our previous work demonstrated that microencapsulation of 3BP reduces its toxicity (Chapiro et al., 2014).
Dose↝, we were only able to reliably deliver multiple doses of the drug intravenously (i.v.), and the number of injections and time periods over which we could administer the drug were limited.
| - |
in-vitro, |
GBM, |
U87MG |
|
|
|
- |
in-vitro, |
Nor, |
HEK293 |
|
|
|
Glycolysis↓, We used the antiglycolytic 3-bromopyruvate (3BP) as a metabolic modifier to treat U118 glioblastoma cell
ROS↑, ROS generated in mitochondria were enhanced at 30 μM 3BP, possibly by unbalancing their generation and their disposal because of glutathione peroxidase inhibition.
GPx↓,
eff↓, Indeed, the scavenger of mitochondrial superoxide MitoTEMPO counteracted 3BP-induced cyt c release and weakened the potentiating effect of 3BP/
OXPHOS↓, (3BP) is a reactive non-specific drug that can act as a metabolic modifier by interfering with glycolysis and oxidative phosphorylation in cancer cells
HK2↓, The mitochondrial hexokinase-II is the main target since its activity is specifically blocked by the formation of a pyruvinyl adduct after reacting with 3BP at the surface of the outer mitochondrial membrane
ATP↓, In malignant tumour cell lines, 3BP inhibits ATPase activity, reduces ATP levels, and reverses chemoresistance by antagonizing drug efflux by acting on the ATP-binding cassette transporters (
ROS↑, Furthermore, 3BP increases the production of reactive oxygen species (ROS) (Ihrlund et al., 2008; Kim et al., 2008; Macchioni et al., 2011a), induces ER stress,
ER Stress↑,
BioAv↓, Unfortunately, prolonged treatment with the drug reduces ROS levels and confers resistance by inducing regulatory genes that act on antioxidant systems.
Cyt‑c↑, 3BP induces cytochrome c release without triggering an apoptotic cascade in U118 cells
Synergy↑, The ROS enhancers antimycin and menadione sensitize U118 cells to 3BP
| - |
in-vitro, |
CRC, |
DLD1 |
|
|
|
- |
NA, |
NA, |
HCT116 |
|
|
|
Synergy↑, Our results demonstrated that the co-treatment of 3-BP and cetuximab synergistically induced an antiproliferative effect in both CRC cell lines
Ferroptosis↓, co-treatment induced ferroptosis, autophagy, and apoptosis.
TumAuto↑,
Apoptosis↑,
FOXO3↑, co-treatment inhibited FOXO3a phosphorylation and degradation and activated the FOXO3a/AMPKα/pBeclin1 and FOXO3a/PUMA pathways, leading to the promotion of ferroptosis, autophagy, and apoptosis in DLD-1
AMPKα↑,
p‑Beclin-1/ATG6↑,
HK2↓, 3-Bromopyruvate (3-BP), also known as hexokinase II inhibitor II, has shown promise as an anticancer agent against various types of cancer
ATP↓, 3-BP exerts its anticancer effects by manipulating cell energy metabolism and regulating oxidative stress, as evidenced by the accumulation of reactive oxygen species (ROS) [13,14,15,16].
ROS↑,
Dose↝, Eight days postinoculation, xenografted mice were randomly divided into four groups and intraperitoneally injected with PBS, 3-BP, cetuximab, or a combination of 3-BP and cetuximab every four days for five injections.
TumVol↓, 3-BP alone or co-treatment with 3-BP and cetuximab significantly reduced the tumor volume and tumor weight on Day 28, but co-treatment showed a greater reduction than 3-BP alone
TumW↓,
xCT/SLC7A11↑, The protein level of SLC7A11 was significantly upregulated in all three cell lines following co-treatment (Fig. 2B).
GSH↓, co-treatment with 3-BP and cetuximab led to glutathione (GSH) depletion (Fig. 2D), reactive oxygen species (ROS) production
eff↓, Knockdown of either ATG5 or Beclin1 attenuated the cell death and MDA production induced by co-treatment
MDA↑,
ATP↓, Advanced cancers (2-3cm) developed and were treated with the alkylating agent 3-bromopyruvate, a lactate/pyruvate analog shown here to selectively deplete ATP and induce cell death.
TumCD↑,
toxicity↓, In all 19 treated animals advanced cancers were eradicated without apparent toxicity or recurrence.
eff↑, These findings attest to the feasibility of completely destroying advanced, highly glycolytic cancers.
tumCV↓, The chemical agent 3-BrPA depletes ATP stores and inhibits HCC cell viability
Dose↝, administered eight treatments on successive days with 1 ml of 2 mM 3-BrPA, also in 1· PBS, pH 7.5. Injection
of 3-BrPA was into the tumor.
TumCG↓, In vivo, animals treated with β-CD–3-BrPA demonstrated minimal or no tumor progression as evident by the BLI signal
toxicity↓, In contrast to animals treated with free 3-BrPA, no lethal toxicity was observed for β-CD–3-BrPA.
BioAv↝, It is possible that in the microencapsulated formulation, 3-BrPA, is more bioavailable for uptake into tumor cells and less available to the normal cells that apparently mediate its toxicity
GAPDH↓, 3-Bromopyruvate (3-BrPA), a highly potent small-molecular inhibitor of the enzyme GAPDH, represents the only available antiglycolytic drug candidate that is able to enter cancer cells selectively through the monocarboxylate transporter 1 (MCT1; refs.
toxicity↑, However, due to its alkylating properties, 3-BrPA is associated with significant toxicity when delivered systemically in therapeutic doses, which has impeded the clinical development and use of this drug in patients with cancer
Dose↝, Encapsulation of 3-BrPA in β-CD was achieved by portionwise addition of 3-BrPA (166 mg, 1 mmol/L) to a stirring solution of β-CD (1,836 mg in 30 mL DI water). The resulting solution was sonicated for 1 hour at room temperature and then shaken overnig
ATP↓, ability of microencapsulated 3-BrPA (β-CD-3-BrPA) to achieve dose-dependent ATP depletion and cell death, two human pancreatic cancer cell lines were employed.
eff↑, both PDAC cell lines were more sensitive to the drugs when hypoxic (Fig. 2)
TumCI↓, MiaPaCa-2 and Suit-2 cells showed a reduction in invasion at drug concentrations as low as 12.5 µmol/L.
MMP9↓, marked reduction in the secretion of MMP-9 was detected in both cell lines.
toxicity↓, No organ toxicities or tissue damage was observed in animals treated with β-CD–3-BrPA
eff↑, Transport of the anti-cancer agent 3-bromopyruvate (3BP) in breast cancer cells is mediated by monocarboxylate transporter (MCT)-1 activated by glycosylated chaperone cluster of differentiation (CD) 147. T
eff↓, The extracellular acidic pH increases the affinity for 3BP uptake enhancing its selective cytotoxic effect in tumour cells.
toxicity↑, 3-Bromopyruvate (3BP), a small alkylating
agent, acts as an anti-metabolite to vital substrates in cancer metabolism and exhibits antitumor activity
across various cancer types, but the unformulated 3BP can cause high toxicity
eff↝, This study explores the efficacy of the 3BP clinical derivative KAT/3BP, currently in phase 1 for patients with hepatocellular carcinoma, in lymphoma models.
eff↑, AT/3BP exhibited synergistic activity when combined with lymphoma therapies, including bendamustine and R-CHOP.
Glycolysis↓, At acidic extracellular pH, 3BP enters cancer cells via monocarboxylic acid-1 (MCT-1) and inhibits glycolysis
through hexokinase II (HK-2) covalent modification
HK2↓, with HK-2 inhibition and dissociation from mitochondria, apoptosis-inducing factor (AIF) release, and apoptosis induction (9).
AIF↑,
Apoptosis↑,
NK cell↑, In the latter, tumor growth was in vivo reversed, with an increase in the number of circulating CD4+, CD8+, and NK-
cells
toxicity↑, unformulated 3BP administrations are associated with severe toxicities, including deaths (22,23)
toxicity↓, However, improvements have been made in developing novel 3BP formulations based on
liposomes, polyethylene glycol (PEG), PEGylated liposomes (stealth liposomes), perillyl alcohol
formulations, and others (12,22,24
Dose↝, KAT-101 and KAT-201 are two clinical 3BP derivatives formulated for oral or intratumoral (IT) administration, respectively (National Cancer Institute Thesaurus Codes C193479 and
C193479), now entering the early clinical evaluation of patients with h
AntiTum↑, KAT/3BP has in vivo antitumor activity in a syngeneic mouse model.
eff↑, Upon oral administration of 3-BP-based agent KAT-101, the 3-BP derivative, being structurally similar to lactic acid, specifically binds to and enters cancer cells through monocarboxylic acid transporters (MCTs)
Glycolysis↓, KAT-101 interferes with both glycolysis and mitochondrial oxidative phosphorylation (OxPhos), thereby depleting adenosine triphosphate (ATP) levels and thus limits energy supply needed by cancer cells to proliferate.
OXPHOS↓,
ATP↓,
TumCP↓,
Apoptosis↑, This induces cancer cell apoptosis and prevents cancer cell proliferation.
HK2↓, In addition, KAT-101 is able to release mitochondrial-bound hexokinase (HK) II (HK2)
MPT↑, increases the formation of mitochondrial permeability transition pores (MPTPs), which induces apoptosis.
LDH↓, KAT-101 also inhibits a variety of enzymes, including lactate dehydrogenase (LDH), pyruvate dehydrogenase (PDH) and pyruvate dehydrogenase kinase (PDHK).
PDH↓,
| - |
in-vitro, |
GBM, |
T98G |
|
|
|
- |
in-vitro, |
GBM, |
LN-18 |
|
|
|
- |
in-vitro, |
GBM, |
U87MG |
|
|
|
Glycolysis↓, we found that 5-ALA, a natural precursor of heme, can hinder cell glycolysis, which is the main path of energy production for most cancer cells.
LDH↓, ore specifically, we found that 5-ALA can block an enzyme involved in glycolysis, called lactate dehydrogenase (LDH)
eff↝, We found that 5-ALA has a potency of LDH inhibition comparable to other established LDH inhibitors, such as oxamate or tartronic acid
ECAR↓, a marked decrease in extracellular acidification rate (ECAR) was registered as a consequence of administering 5-ALA,
AntiCan↑, All treatments resulted in anticancer effects depicted by cell cycle arrest and apoptosis, with TQ demonstrating greater efficacy than CQ10, both with and without 5-FU.
TumCCA↑,
Apoptosis↑,
eff↑, with TQ demonstrating greater efficacy than CQ10, both with and without 5-FU.
Bcl-2↓, However, 5-FU/TQ/CQ10 triple therapy exhibited the most potent pro-apoptotic activity in all cell lines, portrayed by the lowest levels of oncogenes (CCND1, CCND3, BCL2, and survivin)
survivin↓,
P21↑, and the highest upregulation of tumour suppressors (p21, p27, BAX, Cytochrome-C, and Cas-
pase-3).
p27/CDKN1B↑,
BAX↑,
Cyt‑c↑,
Casp3↑,
PI3K↓, The triple therapy also showed the strongest suppression of the PI3K/AKT/mTOR/HIF1α pathway, with a concurrent increase in its endogenous inhibitors (PTEN and AMPKα) in all cell lines used.
Akt↓,
mTOR↓,
Hif1a↓,
PTEN↑,
AMPKα↑,
PDH↑, triple therapy favoured glucose oxidation by upregulating PDH, while decreasing LDHA and PDHK1 enzymes.
LDHA↓,
antiOx↓, most significant decline in antioxidant levels and the highest increases in oxidative stress markers
ROS↑,
AntiCan↑, This study is the first to demonstrate the superior anticancer effects of TQ compared to CQ10, with and without 5-FU, in CRC treatment.
Dose↝, standard diet, a diet containing 2.5% or 5.0% AP or a diet containing 0.2% N-acetylcysteine (NAC) for 10 weeks, using aberrant crypt foci (ACF) as the endpoint.
eff↑, a reduction in the number of aberrant crypts (ACs) and ACF (1-3 AC) were observed in the groups fed with 5.0% AP (37% AC and 47% ACF inhibition, p=0.036) and 0.2% NAC (39% AC and 41% ACF inhibition, p=0.042).
TumNum↓, a reduction in the number of invasive tumors (p<0.005) and tumor multiplicity (p=0.001) was observed in the group fed with 5.0% AP
Ki-67↓, Also, a reduction in tumor Ki-67 cell proliferation (p=0.003) and net growth index (p=0.001) was observed in the group fed with 5.0% AP.
Ingr↝, The seed extract presented 86.26 ± 0.189 mg of catechin/g of extract.
eff↝, The palm and pulp extracts did not exhibit in vitro antitumor activity, while the fruit and seed extracts showed cytotoxic effects on the LNCaP prostate cancer cell line, inducing mitochondrial and nuclear alterations.
Dose↝, Oral treatments were performed daily at 100, 200, and 400 mg/kg of E. oleracea seed extract.
TumVol↓, Treatment at 400 mg/kg reduced the tumor size, nuclear pleomorphism, and mitosis figures, increasing tumor necrosis.
necrosis↑,
IL6↓, The highest doses reduced IL-6 and induced IFN-γ, suggesting antitumor and immunomodulatory effects.
IFN-γ↓,
*Dose?, Healthy volunteers (12) were dosed at 7 mL/kg of body weight after a washout phase and overnight fast, and plasma was repeatedly sampled over 12 h and urine over 24 h after consumption.
*BioAv↝, total anthocyanins quantified as cyanidin-3-O-glucoside showed Cmax values of 2321 and 1138 ng/L at t max times of 2.2 and 2.0 h, and AUC last values of 8568 and 3314 ng h L(-1) for pulp and juice, respectively.
*eff↑, plasma antioxidant capacity of up to 2.3- and 3-fold for acai juice and pulp, respectively were observed
*BOLD↑, Following daily supplementation for 16 weeks, blueberry-treated participants exhibited increased BOLD activation in the left pre-central gyrus, left middle frontal gyrus, and left inferior parietal lobe during working memory load conditions
*cognitive?, consistent with prior trials showing neurocognitive benefit with blueberry supplementation in this at-risk population.
*eff↑, High-flavanol cocoa treatment has been associated with enhancement of cerebral blood flow, [9] Concord grape juice [10] and pomegranate juice [11] supplementation with increased regional brain activation, and resveratrol treatment with enhanced hippo
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*cardioP↑, Epidemiological studies associate regular, moderate intake of blueberries and/or anthocyanins with reduced risk of cardiovascular disease, death, and type 2 diabetes, and with improved weight maintenance and neuroprotection.
*neuroP↑,
*Inflam↓, Among the more important healthful aspects of blueberries are their anti-inflammatory and antioxidant actions and their beneficial effects on vascular and glucoregulatory function
*antiOx↓,
*GutMicro↑, Blueberry phytochemicals may affect gastrointestinal microflora and contribute to host health
*Half-Life↑, However, >50% of the 13C still remained in the body after 48 h
*LDL↓, controlled study of 58 diabetic patients, blueberry intake led to a decline in LDL cholesterol, triglycerides, and adiponectin and an increase in HDL cholesterol
*adiP↓,
*HDL↑,
*CRP↓, reduction was documented in inflammatory markers, including serum high-sensitivity C-reactive protein, soluble vascular adhesion molecule-1, and plasma IL-1β
*IL1β↓,
*Risk↓, lower Parkinson disease risk was associated with the highest quintile of anthocyanin (RR: 0.76) and berry (RR: 0.77) intake
*Risk↓, Nurse's Health Study, greater intake of blueberries and strawberries was associated with slower rates of cognitive decline in older adults, with an estimated delay in decline of about 2.5 y
*cognitive↑, Cognitive performance in elderly adults improved after 12 wk of daily intake of blueberry (94) or Concord grape (95) juice.
*memory↑, Better task switching and reduced interference in memory was found in healthy older adults after 90 d of blueberry supplementation
*other↑, After 12 wk of blueberry consumption, greater brain activity was detected using magnetic resonance imaging in healthy older adults during a cognitive challenge.
*BOLD↑, Similarly, during a memory test, regional blood oxygen level-dependent activity detected by MRI (99) was enhanced in the subjects taking blueberry, but not in those taking placebo.
*NO↓, 50–200 mg/d bilberry showed a dose-dependent decrease in neurotoxic NO and malondialdehyde, combined with an increase in neuroprotective antioxidant capacity due to glutathione, vitamin C, superoxide dismutase, and glutathione peroxidase
*MDA↓,
*GSH↑,
*VitC↑,
*SOD↑,
*GPx↑,
*eff↓, The percentage loss of blueberry anthocyanins during −18°C storage was 12% after 10 mo of storage
*eff↓, Freeze-dried blueberry powder loses anthocyanins in a temperature-dependent manner with a half-life of 139, 39, and 12 d when stored at 25, 42, and 60°C, respectively
*eff↓, Blueberries are low in ascorbic acid and high in anthocyanins (187), and notably anthocyanins are readily degraded by ascorbic acid
*eff↝, Shelf-stable blueberry products like jam (196), juice (197), and extracts (198) can lose polyphenolic compounds when stored at ambient temperature whereas refrigeration mitigates losses.
*Risk↓, It can be safely stated that daily moderate intake (50 mg anthocyanins, one-third cup of blueberries) can mitigate the risk of diseases and conditions of major socioeconomic importance in the Western world.
eff↑, Saskatoon berry and wild blueberry showed a high content of total anthocyanins (562.4 and 558.3 mg/100 g, respectively) that were not significantly (P>0.05) different from each other.
TrxR↓, Auranofin (Au), an inhibitor of thioredoxin reductase, is a known anti‑cancer drug
AntiCan↑,
TumCG↓, Au inhibited the growth of HeLa cells with an IC50 of ~2 µM at 24 h.
Apoptosis↑, This agent induced apoptosis and necrosis, accompanied by the cleavage of poly (ADP‑ribose) polymerase and loss of mitochondrial membrane potential.
necrosis↑,
cl‑PARP↑,
MMP↓,
ROS↑, With respect to the levels of ROS and GSH, Au increased intracellular O2•- in the HeLa cells and induced GSH depletion.
GSH↓,
eff↓, The antioxidant, N‑acetyl cysteine, not only attenuated apoptosis and necrosis in the Au‑treated HeLa cells, but also decreased the levels of O2•- and GSH depletion in the cells.
TrxR↓, Auranofin (AF) is an FDA-approved antirheumatic drug with anticancer properties that acts as a thioredoxin reductase 1 (TrxR) inhibitor.
AntiCan↓,
GPx4↓, Although functionally AF appeared a potent inhibitor of GPX4 in all NCI–H1299 cell lines, the induction of lipid peroxidation and consequently ferroptosis was limited to the p53 R273H expressing cells.
DNAdam↑, AF mainly induced large-scale DNA damage and replication stress, leading to the induction of apoptotic cell death rather than ferroptosis.
toxicity↓, AF is an orally available, lipophilic, organogold compound with a well-known safety profile that was approved by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis (RA).
eff↝, AF represents a potential novel therapeutic strategy to efficiently kill mutant p53 NSCLC tumor cells through distinct immunogenic cell death pathways.
ROS↑, AF primarily functions as a pro-oxidant by inhibiting thioredoxin reductase (TrxR), an antioxidant enzyme overexpressed in ovarian cancer.
TrxR↓, The primary mechanism of action of auranofin is to act as a pro-oxidative agent, increasing the production of reactive oxygen species (ROS) as a consequence of inhibiting the thioredoxin reductase (TrxR) anti-oxidant system
MMP↓, triggers the depolarization of the mitochondrial membrane, and kills HGSOC cells by inducing apoptosis.
Apoptosis↑,
eff↓, Notably, AF-induced cell death was abrogated by the ROS-scavenger N-acetyl cysteine (NAC).
Casp3↑, lethality of AF was associated with the activation of caspases-3/7 and the generation of DNA damage
Casp7↑,
DNAdam↑,
Synergy↑, Finally, when AF and L-BSO were combined, we observed synergistic lethality against HGSOC cells, which was mediated by a further increase in ROS and a decrease in the levels of the antioxidant GSH.
GSH↓,
angioG↓, Additionally, auranofin has been shown to inhibit angiogenesis
ChemoSen↑, In this study, we identified the mechanisms of cytotoxicity induced by auranofin in HGSOC cells that have different clinical sensitivities to platinum.
cl‑PARP↑, the cleavage of poly-ADP ribose polymerase (PARP), and the polyubiquitination of proteins
Synergy↑, synergistic lethal interaction between auranofin and a second pro-oxidant agent, the glutathione (GSH) inhibitor, L-buthionine sulfoximine (L-BSO);
RadioS↑, AF at 3–10 μM is a potent radiosensitizer in vitro
ROS↑, . The first one is linked to an oxidative stress, as scavenging of reactive oxygen species (ROS)
eff↓, N-acetyl cysteine counteracted radiosensitization. (NAC)
mt-OCR↓, We also observed a decrease in mitochondrial oxygen consumption with spared oxygen acting as a radiosensitizer under hypoxic conditions.
DNAdam↑, Overall, radiosensitization was accompanied by ROS overproduction, mitochondrial dysfunction, DNA damage and apoptosis
Apoptosis↑,
TrxR↓, targeting thioredoxin reductase (TrxR)
eff↑, a simultaneous disruption of the thioredoxin and glutathione systems by the combination of AF and buthionine sulfoximine was shown to significantly improve tumor radioresponse.
TrxR↓, Gold derivatives are irreversible inhibitors of TrxR. Among them, auranofin (AF), a selective TrxR inhibitor, has proven its effectiveness as a drug for the treatment of rheumatoid arthritis
BioAv↓, further clinical application of AF could be challenging due to the low solubility and insufficient delivery to glioblastoma.
ROS↑, The inhibition of TrxR1, which leads to increased ROS levels, is currently recognized as the primary mechanism of AF cytotoxicity [106]. In vitro studies have also shown that AF inhibits other thioredoxin reductases, such as TrxR2 and TrxR3
eff↝, The literature indicates that not all cancer tumors exhibit the same level of TrxR expression, affecting their sensitivity to AF.
TET1?, AF was shown to inhibit TET1 in T-ALL models
CompStab↑, Encapsulating AF into nanoparticles or combining it with other pharmaceutical excipients can minimize its potential adverse effects, preserve its interaction with serum proteins, and result in greater stability.
TrxR↓, Auranofin mainly targets the anti-oxidative system catalyzed by thioredoxin reductase (TrxR), which protects the cell from oxidative stress and death in the cytoplasm and the mitochondria.
ROS↑, Inhibiting TrxR dysregulates the intracellular redox state causing increased intracellular reactive oxygen species levels, and stimulates cellular demise
eff↑, TrxR is over-expressed in many cancers as an adaptive mechanism for cancer cell proliferation, rendering it an attractive target for cancer therapy, and auranofin as a potential therapeutic agent for cancer.
Apoptosis↑, promotion of ASK-induced apoptosis, and blockage of cell growth, proliferation, and survival due to reduced AKT activity and NF-kB- and p53-mediated transcription.
TumCG↓,
TumCP↓,
Akt↓,
NF-kB↓,
DNAdam↑, DNA damage
eff↝, auranofin inhibits TrxR1 in a p53-independent manner
eff↓, Pre-treatment with NAC counteracted the cancer cell killing effects of auranofin,
PI3K↓, auranofin induces cytotoxicity in human pancreatic adenocarcinoma and non-small cell lung cancer via the inhibition of the PI3K/AKT/mTOR pathway
Akt↓,
mTOR↓,
Hif1a↓, auranofin inhibits the cancer cell response to hypoxia, demonstrated by a decrease in HIF-1 𝛼 expression and VEGF secretion upon auranofin treatment under hypoxic conditions
VEGF↓,
Casp3↑, auranofin was shown to induce caspase-3-mediated apoptosis in human ovarian carcinoma SKOV-3 cells
CSCs↓,
ATP↓, it was found that auranofin inhibits ABCG2 function by depleting cellular ATP via inhibition of glycolysis [96]
Glycolysis↓,
Synergy↑, auranofin synergizes with another Trx1 inhibitor, piperlongumine, in killing gastric cancer cells in association with ROS-mediated ER stress response and mitochondrial dysfunction.
eff↑, when the gold complex is combined with either selenite or tellurite [104]
MMP↓, Increased ROS induced by AUR causes decreased membrane potential in the mitochondrial membrane, resulting in a decrease in anti-apoptotic proteins, caspase-dependent cell death, and translocation of apoptosis-inducing factor (AIF)
AIF↑,
toxicity↓, Auranofin is considered safe for human use in treating rheumatoid arthritis; thus, this gold derivative can reach the clinic for other diseases relatively quickly and at a low cost
TrxR↓, AF treatment decreased TrxR activity and clonogenic survival in small cell lung cancer (SCLC) cell lines (DMS273 and DMS53) as well as the lung atypical (neuroendocrine tumor) NET cell line H727.
eff↑, AF treatment also significantly sensitized DMS273 and H727 cell lines in vitro to sorafenib, a multi-kinase inhibitor that was shown to decrease intracellular glutathione.
Dose↝, AF was administered intraperitoneally at 2 mg/kg or 4 mg/kg (IP) once (QD) or twice daily (BID) for 1 to 5 days in mice with DMS273 xenografts.
OS↑, When this daily AF treatment was extended for 14 days a significant prolongation of median survival from 19 to 23 days (p=0.04, N=30 controls, 28 AF) was observed without causing changes in animal bodyweight, CBCs, bone marrow toxicity, blood urea ni
eff↑, We also demonstrated that suppressing TrxR with AF can sensitize breast cancer stem cells to ROS induced stem cell transitions associated with EMT and cytotoxicity associated with 2-deoxyglucose treatment.
TrxR↓, Auranofin inhibits the activity of thioredoxin reductase (TrxR
ROS↑, TrxR inhibition leads to an increase in cellular oxidative stress and induces apoptosis
Apoptosis↓,
TumCP↓, TrxR1 knockdown also inhibits cancer cell proliferation and DNA replication
eff↑, cytotoxicity of cisplatin is increased in cells expressing high levels of TrxR1 compared with cells expressing low levels
*Imm↑, AR possesses various biological functions, including potent immunomodulation, antioxidant, anti-inflammation and antitumor
activities.
*antiOx↑,
*Inflam↓,
AntiTum↑,
eff↑, characteristics of increasing curative effect and reducing the toxicity of chemotherapeutic drugs [11 , 118].
chemoP↑,
Dose↝, main bioactive compounds responsible for the anti-cancer effects of AR mainly include formononetin,
AS-IV and APS. S
TumCMig↓, AS-IV could inhibit the migration and proliferation of non-small cell lung cancer (NSCLC
TumCP↓,
Akt↓, h via inhibition of the Akt/GSK-3β/β-catenin
signaling axis.
GSK‐3β↓,
MMP2↓, downregulating the expression of matrix metalloproteases (MMP)-2 and -9
MMP9↓,
EMT↓, AS-IV could inhibit TGF-B1 induced EMT through inhibition of PI3K/AKT/NF-KB
PI3K↓,
Akt↓,
NF-kB↓,
Inflam↓,
TGF-β1↓,
TNF-α↓,
IL6↓,
Fas↓, reduced FAS/FasL
FasL↓,
NOTCH1↓, decressing notch1
JNK↓, inactivating JNK pathway [145]
TumCG↓, The results showed that the AR water extract could inhibit the growth of colorectal cancer in vivo without apparent toxicity and side effect, which suggests that AR is a potential therapeutic drug for colorectal cancer
AntiTum↑, APS has been increasingly used in cancer therapy owing to its anti-tumor ability as it prevents the progression of prostate, liver, cervical, ovarian, and non-small-cell lung cancer by suppressing tumor cell growth and invasion and enhancing apoptosi
TumCG↓,
TumCI↓,
Apoptosis↑, after APS treatment, the apoptosis of HepG2 cells is accelerated (57).
Imm↑, APS enhances the sensitivity of tumors to antineoplastic agents and improves the body’s immunity
Bcl-2↓, Huang et al. proposed that APS induces H22 (a hepatocellular cancer [HCC] cell line) apoptosis by downregulating Bcl-2 and upregulating Bax expression (56).
BAX↑,
Wnt↓, downregulating the Wnt/β-catenin signaling pathway.
β-catenin/ZEB1↓,
TumCG↓, APS effectively inhibited the growth of MDA-MB-231 (a human breast cancer [BC] cell line) graft tumor (58)
miR-133a-3p↑, apoptosis rate of human osteosarcoma MG63 cells increased owing to the upregulation of miR-133a and inactivation of the JNK signaling pathways (71).
JNK↓,
Fas↑, Li and Shen found that APS can induce apoptosis by activating the Fas death receptor pathway.
P53↑, Zhang et al. showed that APS could activate p53 and p21 and inhibit the expression of Notch1 and Notch3 in vitro, ultimately inhibiting cell proliferation and promoting their apoptosis
P21↑,
NOTCH1↓,
NOTCH3↓,
TumCP↓,
TumCCA↑, Liu et al. found that APS induced the cell cycle of bladder cancer UM-UC-3 to stop in the G0/G1 phase, thus inhibiting its proliferation
GPx4↓, APS was found to reduce GPX4 expression, inhibit the activity of the light chain subunit SLC7A11 (xCT), and promote the formation of BECN1-xCT complex by activating AMPK/BECN1 signaling.
xCT/SLC7A11↓,
AMPK↑,
Beclin-1/ATG6↑,
NF-kB↓, APS could control the proliferation of lung cancer cells (A549 and NCI-H358 cells) by inhibiting the NF-κB signaling pathway (97)
EMT↓, APS treatment led to reduced EMT markers (vimentin, AXL) and MIF levels in cells.
Vim↓,
TumMeta↓, APS inhibits Lewis lung cancer growth and metastasis in mice by significantly reducing VEGF and EGFR expression in cancerous tissues
VEGF↓,
EGFR↓,
eff↑, Nano-drug delivery systems can increase efficiency and reduce toxicity
eff↑, Jiao et al. developed selenium nanoparticles modified with macromolecular weight APS and observed positive results in hepatoma treatment
MMP↓, Subsequent investigations revealed that APS can decrease the ΔΨm values and Bcl-2, p-PI3K, P-gp, and p-AKT levels while elevating Bax expression.
P-gp/ABCB1↓,
MMP9↓, downregulation of MMP-9 expression,
ChemoSen↑, Li et al. observed that APS could enhance the sensitivity of SKOV3 ovarian cancer cells to CDDP treatment by activating the mitochondrial apoptosis pathway and JNK1/2 signaling pathway
SIRT1↓, APS significantly suppressed SIRT1 and SREBP1 expression, decreased cholesterol and triglyceride levels in PC3 and DU145, and attenuated cell proliferation.
SREBP1/SREBF1↓,
TumAuto↑, APS can induce autophagy in colorectal cancer cells by inhibiting the PI3K/AKT/mTOR axis and the development of cancer cells.
PI3K↓,
mTOR↓,
Casp3↑, Shen found that APS elevated caspase-9, caspase-3, and Bax protein levels, decreased Bcl-2 protein expression, and inhibited CD133 and CD44 co-positive colon cancer stem cell proliferation time
Casp9↑,
CD133↓,
CD44↓,
CSCs↓,
QoL↑, QOL was significantly improved as indicated by the reduction in pain and improvement in appetite
ChemoSen↑, review aims to determine the clinical efficacy and safety of Astragalus Polysaccharide Injection (APS) combined with chemoradiotherapy for cervical cancer based on existing data.
eff↑, APS combined with chemoradiotherapy improved the objective response rate (ORR, RR = 1.43, 95% CI: 1.24–1.64) and disease control rate (
RadioS↑, APS can enhance the clinical efficacy of radiotherapy and chemotherapy for cervical cancer, respectively.
CEA↓, APS further reduced tumor marker levels: CEA (MD = −1.24, 95% CI: −1.58 to −0.89, p < 0.00001; heterogeneity: χ2 = 1.75, p = 0.19, I2 = 43%), SCC (
Wnt↓, Specifically, APS inhibits the cisplatin resistance pathway and regulates the cell cycle by suppressing the Wnt/β-catenin pathway via the PPARD/CDC20 axis (Liu et al., 2025)
β-catenin/ZEB1↓,
γH2AX↑, APS also influences autophagy and upregulates γH2AX expression, thereby enhancing cervical cancer sensitivity to radiotherapy
ER Stress↑, APS alleviates endoplasmic reticulum stress and promotes mitochondrial autophagy, thereby enhancing apoptosis and mitigating cisplatin-induced toxicity
mt-TumAuto↑,
QoL↑, suggested that APS combination therapy improves short-term clinical efficacy, quality of life, and immune function
Imm↑,
AntiCan↑, Preclinical studies indicate that APS exerts significant anti-liver cancer effects through multiple biological actions, including the promotion of apoptosis, inhibition of proliferation, suppression of epithelial–mesenchymal transition, regulation of
Apoptosis↑,
TumCP↓,
EMT↓,
Imm↑, improving host immune response
ChemoSen↑, APS exhibits synergistic effects when combined with conventional chemotherapeutics and interventional treatments such as transarterial chemoembolisation, improving efficacy and reducing toxicity.
BioAv↓, limitations such as low bioavailability and a lack of large-scale clinical trials remain challenges for clinical translation.
TumCG↓, APS significantly inhibited tumour growth in H22-bearing mice with a dose-dependent effect (100, 200, 400 mg/kg), with the 400 mg/kg group achieving a tumour inhibition rate of 59.01%
IL2↑, APS enhance the thymus and spleen indices and elevates the key cytokines, including IL-2, IL-12, and TNF-α.
IL12↑,
TNF-α↑,
P-gp/ABCB1↓, APS reversed chemoresistance by downregulating P-glycoprotein and MDR1 mRNA expression
MDR1↓,
QoL↑, These effects contributed to improved treatment tolerance and enhanced quality of life [39].
Casp↑, APS can activate both the intrinsic and extrinsic apoptotic pathways, leading to caspase activation and DNA fragmentation
DNAdam↑,
Bcl-2↓, Mechanistically, APS downregulate antiapoptotic proteins such as Bcl-2 while upregulating proapoptotic proteins such as Bax and cleaved caspase-3.
BAX↑,
MMP↓, APS have been shown to disrupt the mitochondrial membrane potential and promote the release of cytochrome c, thereby enhancing apoptotic cascades in hepatocellular carcinoma models.
Cyt‑c↑,
NOTCH1↓, APS (0.1, 0.5, and 1.0 mg/mL) were shown to reduce both mRNA and protein levels of Notch1 in a concentration-dependent manner.
GSK‐3β↓, APS significantly inhibited the proliferation of HepG2 cells by downregulating the expression of glycogen synthase kinase-3β (GSK-3β), with 200 μg/mL being the most effective concentration.
TumCCA↑, APS exerted these effects by inducing cell cycle arrest at the G2/M and S phases, thereby impeding tumour cell proliferation [35].
GSH↓, HepG2 cells. APS also reduced intracellular glutathione (GSH) levels, increased reactive oxygen species (ROS) and lipid peroxidation levels, and elevated intracellular iron ion concentrations—all in a dose-dependent manner.
ROS↑,
lipid-P↑,
c-Iron↑,
GPx4↓, APS treatment led to the downregulation of GPX4 and upregulation of ACSL4, indicating that APS promotes ferroptosis in liver cancer cells.
ACSL4↑,
Ferroptosis↑,
Wnt↓, inhibit the expression of key proteins involved in the Wnt/β-catenin signalling pathway
β-catenin/ZEB1↓,
cycD1/CCND1↓, by downregulating the key oncogenic targets, including β-catenin, C-myc, and cyclin D1, which subsequently reduces Bcl-2 expression and activates the apoptotic cascade in HepG2 liver cancer cells.
Akt↓, It also inhibited the Akt/p-Akt signalling pathway.
PI3K↓, APS inhibit the PI3K/AKT/mTOR signalling pathway, which is a central negative regulator of autophagy.
mTOR↓,
CXCR4↓, PS upregulated the epithelial marker E-cadherin while downregulating the mesenchymal marker vimentin and the chemokine receptor CXCR4 at both mRNA and protein levels, suggesting that APS suppress liver cancer cell growth and metastasis by inhibiting
Vim↓,
PD-L1↓, APS interfere with immune checkpoint signalling by downregulating Programmed death-ligand 1 (PD-L1) expression on tumour cells.
eff↑, The preparation of polysaccharide–SeNP composites typically involves using sodium selenite (Na2SeO3) as the precursor and ascorbic acid (Vc) as the reducing agent, with synthesis carried out via a chemical reduction method in a polysaccharide solutio
eff↑, Mechanistic investigations revealed that AASP–SeNPs elevated intracellular ROS levels and reduced the mitochondrial membrane potential (∆Ψm).
ChemoSen↑, APS enhance doxorubicin-induced endoplasmic reticulum (ER) stress by reducing O-GlcNAcylation levels, thereby promoting apoptosis of liver cancer cells.
ChemoSen↑, APS inhibited BEL-7404 human liver cancer cell growth in a concentration-dependent manner and showed stronger cytotoxicity when combined with cisplatin.
chemoP↑, APS protects against chemotherapy-induced liver injury, particularly that caused by CTX, through antiapoptotic mechanisms
eff↑, We found a large treatment effect of adding astragalus-based herbal treatment to standard chemotherapy regimens.
ChemoSen↑,
| - |
in-vitro, |
Liver, |
HepG2 |
|
|
|
- |
in-vitro, |
Nor, |
L02 |
|
|
|
tumCV↓, AgNPs induced a concentration-dependent decline in HepG2 and L02 cells viability.
ROS↑, •
AgNPs induced ROS increase and apoptosis in HepG2 and L02 cells.
*ROS↑,
DNAdam↑, AgNPs induced DNA damage, autophagy and cell cycle arrest in HepG2 and L02 cells.
*DNAdam↑,
eff↓, N-acetylcysteine (NAC)alleviated AgNPs-induced cytotoxicity in HepG2 and L02 cells.
selectivity↑, Interestingly, HepG2 cells were more sensitive to AgNPs than L02 cells, and this may be related to the different ROS generation and responses to AgNPs by cancer cells and normal cells.
Ferroptosis↑, we provide evidence that AgNPs trigger ferroptosis in both mouse hepatocytes and HepG2 cells
p62↑, AgNPs increased p62 expression, which in turn stabilized Nrf2 by suppressing its interaction with Keap1.
NRF2↝,
eff↓, Upon activation, Nrf2 enhances the transcription of key antioxidant enzymes, including NQO1 and HO-1, thereby alleviating ferroptosis.
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
BPH, |
NA |
|
|
|
ROS↑, capacity of these nanostructures to release silver ions (Ag+) and enhance the production of reactive oxygen species (ROS) has been explored in combination with light to treat several diseases.
EPR↓, Furthermore, the use of NPs in biomedical applications takes advantage of the enhanced permeability and retention (EPR) effect, a phenomenon that enables greater penetration and longer retention times in cancer cells compared to normal cells
Synergy↑, When the AgNPs are exposed to an electromagnetic field, the electrons in the metals’ conduction band oscillate collectively and in resonance with the light frequency, generating the LSPR at the AgNPs’ surface.
Bacteria↓, NPs have already been approved by the Food and Drug Administration (FDA) as antibacterial agents for clinical use [
eff↑, Smaller AgNPs have been appointed as having greater reactivity compared to larger ones, due to their higher surface area-to-volume ratio and enhanced cellular uptake.
eff↑, TSC-coated AgNPs exhibited stronger binding affinity to Gram-positive bacteria, while the positively charged AgNPs-TMA were more efficiently internalized by Gram-negative bacteria.
TumVol↓, After PTT treatment with a AgNPs-PVP dose of 50 mg.kg−1 for 5 min, the prostate size of the BPH-bearing animals was reduced compared with non-treated rats, showing that AgNPs could prevent the progression of BHP.
| - |
in-vivo, |
Ovarian, |
A2780S |
|
|
|
- |
NA, |
Ovarian, |
SKOV3 |
|
|
|
Fenton↑, Chemodynamic therapy (CDT) holds great promise in achieving cancer therapy through Fenton and Fenton-like reactions, which generate highly toxic reactive species
ROS↑, can decompose already existing intracellular H2O2 and produce reactive oxygen species (ROS) to attain a therapeutic outcome.
eff↑, Ag+, Fe2+) based silver pentacyanonitrosylferrate or silver nitroprusside (AgNP) were developed for Fenton like reactions that can specifically kills cancer cells by taking advantage of tumor acidic environment without used of any external stimuli
angioG↓, been reported that Ag-based materials are involved in angiogenesis inhibition by blocking Akt phosphorylation
p‑Akt↓,
EPR↑, These results indicate thatin cancer cell lines internalized AgNP, which partially localized inysosomes and could be relocalized to cytoplasm avoiding degradation due to lysosomal acidic pH, which produce ROS.
selectivity↑, While, in normal fibroblast cells over time AgNP colocalization in lysosomes increased due to the difference in lysosomal pH between cancer
and normal cells
selectivity↑, results suggest that AgNP specifically produces ROS in cancer cell lines due to high acidity in comparison to the normal cells.
eff↑, This specific ROS production is probably due to tumor
acidic environment in which AgNP act as a Fenton reagent
Cyt‑c↑, Cytochrome c release after AgNP treatment
HO-1↑, In A2780 cell line, HO-1 expression levels increased 8.1-fold when treated with AgNP
TrxR↓, 183(Au) was able to decrease TrxR activity by 50% at 4.20 nM
eff↓, IC 50 value calculated for 184(Ag) was 10.30 nM
eff↓, Conversely, 185(Cu) was found to be much less effective in inhibiting TrxR activity, with an IC 50 value of 89.50 nM
TrxR↓, accumulate into cancer cells and to selectively target Thioredoxin (TrxR),
eff↝, 2 µM was able to decrease TrxR enzyme activity by about 68%, compared with auranofin, which at the same concentration
ROS↑, cellular production of reactive oxygen species (ROS)
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
Melanoma, |
A375 |
|
|
|
- |
in-vitro, |
Colon, |
HCT15 |
|
|
|
- |
in-vitro, |
Cerv, |
HeLa |
|
|
|
TrxR↓, In particular, [Au(PTA)4]PF6 was able to decrease by 50% TrxR activity at 4.2 nM
eff↓, C 50 value calculated for [Ag(PTA) 4]PF6 was 10.3 nM.
eff↓, Conversely, [Cu(PTA)4]PF6 was found to be much less effective in inhibiting this cytosolic selenoenzyme, with an IC50 value of 89.5 nM, roughly from 9 to 21 times higher than those calculated for silver and gold derivatives,
other∅, To the best of our knowledge, this is the first example of a phosphino silver complex acting as TrxR inhibitor.
eff↑, Here, a pure physical method is used to efficiently fabricate very small silver particles even approaching the Ångstrom (Ång) dimension.
eff↑, Fructose is used as a dispersant and stabilizer to coat the Ång-scale silver particles (AgÅPs).
Apoptosis↑, (F-AgÅPs) can enter and accumulate in multiple cultured cancer cell lines to induce apoptotic death, whereas most normal cells are resistant to the efficacious dose of F-AgÅPs;
selectivity↓,
TumCG↓, intravenous administration of F-AgÅPs potently inhibits the growth of pancreatic and lung cancer xenografts in nude mice, without inducing notable toxic effects on the healthy tissues.
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
Nor, |
HEK293 |
|
|
|
NRF2↑, Nanosilver increased Nrf2 protein expression and disrupted the cell cycle at the G1 and G2/M phases.
TumCCA↑, AgNPs interact with DNA to stop
the cell cycle and lead to apoptosis
ROS↑, Nanosilver induced significant mitochondrial oxidative stress in HCT116, whereas it did not in the non-cancer HIEC-6 and nanosilver/sodium ascorbate co-treatment was preferentially lethal to HCT116 cells,
selectivity↑,
*AntiViral↑, AgNPs are effective antiviral agents against various viruses such as human
immunodeficiency virus, hepatitis B virus, and monkey pox virus through interaction with
surface glycoproteins on the virus
*toxicity↝, Citrate and PVP-coated AgNPs have been found to be less toxic than non-coated AgNPs
ETC↓, AgNPs affects mitochondrial function through the disruption of the electron transport
chain2,24,26,33,39–41
MMP↓, Studies have shown that exposure to AgNPs resulted in a decrease of mitochondrial membrane potential (MMP) in various in vitro and in vivo experiments
DNAdam↑, AgNPs has also been shown to interact with and induce damage to DNA, DNA strand breaks, DNA damage
Apoptosis↑, apoptosis induced by AgNPs were through membrane lipid peroxidation, ROS, and oxidative stress
lipid-P↑,
other↝, Several studies have showed AgNPs interact with various proteins such as haemoglobin, serum albumin, metallothioneins, copper transporters, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), malate dehydrogenase (MDH), and bacterial proteins.
UPR↑, Studies have shown exposure to AgNPs induces activation of the UPR
*GRP78/BiP↑, AgNPs induced increased levels of GRP78, phosphorylated PERK, phosphorylated eIF2-α, and
phosphorylated IRE1α, spliced XBP1, cleaved ATF-6, CHOP, JNK and caspase 12
*p‑PERK↑,
*cl‑eIF2α↑,
*CHOP/DDIT3↑,
*JNK↑,
Hif1a↓, One study showed AgNPs inhibits HIF-1 accumulation and suppresses expression of HIF-1 target genes in breast cancer cells (MCF-7) and also found the protein
levels of HIF-1α and HIF-1β decreased
AntiCan↑, Many studies have shown that ascorbic acid, on its own, has anti-cancer effects
*toxicity↓, However, when the rats were treated with both ascorbic acid
and AgNPs, a decrease in toxic effects was observed in non-cancer parotid glands in rats
eff↑, Studies have shown both AgNPs and ascorbic acid have greater effects and toxicity in
cancer cells relative to non-cancer cells
Telomerase↓, AgNPs could inhibit telomerase activity and lead to telomere shortening and dysfunction.
eff↝, Overexpression of telomerase attenuated the anticancer activity of AgNPs, whereas downregulation of telomerase activity or dysfunction of the telomere enhanced the cytotoxicity of AgNPs in HeLa cells.
| - |
in-vitro, |
Nor, |
RAW264.7 |
|
|
|
*Wound Healing↑, unique antimicrobial properties silver nanocrystallites have garnered substantial attention and are used extensively for biomedical applications as an additive to wound dressings, surgical instruments and bone substitute materials.
*eff↝, cytotoxicity was dependent on various factors such as surface charge and coating materials used in the synthesis, particle aggregation, and the cell-type for the different silver nanoparticles that were investigated.
*toxicity↝, uncoated or colloidal silver nanoparticles were found to be the least toxic to both macrophage and lung epithelial cells
AntiCan↑, iologically synthesized silver nanoparticles induced apoptosis, and showed a cytotoxic and anti-cancer effect against gastric cancer cell lines in a dose- and time-dependent manner.
Apoptosis↑,
eff↑, Biologically synthesized nanoparticles may possess higher anti-cancer properties than commercial silver
ROS↑, graphical abstract
DNAdam↑, inducing cell death through apoptotic signaling pathways, and inducing excess reactive oxygen species (ROS) in tumor cells, which leads to oxidative damage and increased production of proapoptotic enzymes
TumCCA↑,
eff↑, Metallic nanoparticles, especially those derived from metals, improve the effectiveness of anticancer agents by facilitating targeted delivery and sustained release at tumor sites.
Apoptosis↑,
eff↓, Au NPs are notable for their biocompatibility and are utilized in photothermal therapy to convert light into heat, effectively destroying cancer cells
ChemoSen↑, Magnesium oxide nanoparticles (MgO NPs) induce apoptosis through ROS production and enhance the impact of chemotherapy drugs, synthesized with plant extracts as reducing agents.
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
Diabetic, |
NA |
|
|
|
ROS↑, action mechanisms of AgNPs, which mainly involve the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure.
eff↑, briefly introduce a new type of Ag particles smaller than AgNPs, silver Ångstrom (Å, 1 Å = 0.1 nm) particles (AgÅPs), which exhibit better biological activity and lower toxicity compared with AgNPs.
other↝, This method involves reducing silver ions to silver atoms 9, and the process can be divided into two steps, nucleation and growth
DNAdam↑, antimicrobial mechanisms of AgNPs includes destructing bacterial cell walls, producing reactive oxygen species (ROS) and damaging DNA structure
EPR↑, Due to the enhanced permeability and retention (EPR) effect, tumor cells preferentially absorb NPs-sized bodies than normal tissues
eff↑, Large surface area may lead to increased silver ions (Ag+) released from AgNPs, which may enhance the toxicity of nanoparticles.
eff↑, Our team prepared Ångstrom silver particles, capped with fructose as stabilizer, can be stable for a long time
TumMeta↓, AgNPs can induce tumor cell apoptosis through inactivating proteins and regulating signaling pathways, or blocking tumor cell metastasis by inhibiting angiogenesis
angioG↓, Various studies support that AgNPs can deprive cancer cells of both nutrients and oxygen via inhibiting angiogenesis
*Bacteria↓, Rather than Gram-positive bacteria, AgNPs show a stronger effect on the Gram-negative ones. This may be due to the different thickness of cell wall between two kinds of bacteria
*eff↑, In general, as particle size decreases, the antibacterial effect of AgNPs increases significantly
*AntiViral↑, AgNPs with less than 10 nm size exhibit good antiviral activity 185, 186, which may be due to their large reaction area and strong adhesion to the virus surface.
*AntiFungal↑, Some studies confirm that AgNPs exhibit good antifungal properties against Colletotrichum coccodes, Monilinia sp. 178, Candida spp.
eff↑, The greater cytotoxicity and more ROS production are observed in tumor cells exposed to high positive charged AgNPs
eff↑, Nanoparticles exposed to a protein-containing medium are covered with a layer of mixed protein called protein corona. formation of protein coronas around AgNPs can be a prerequisite for their cytotoxicity
TumCP↓, Numerous experiments in vitro and in vivo have proved that AgNPs can decrease the proliferation and viability of cancer cells.
tumCV↓,
P53↝, gNPs can promote apoptosis by up- or down-regulating expression of key genes, such as p53 242, and regulating essential signaling pathways, such as hypoxia-inducible factor (HIF) pathway
HIF-1↓, Yang et al. found that AgNPs could disrupt the HIF signaling pathway by attenuating HIF-1 protein accumulation and downstream target genes expression
TumCCA↑, Cancer cells treated with AgNPs may also show cell cycle arrest 160, 244
lipid-P↑, Ag+ released by AgNPs induces oxidation of glutathione, and increases lipid peroxidation in cellular membranes, resulting in cytoplasmic constituents leaking from damaged cells
ATP↓, mitochondrial function can be inhibited by AgNPs via disrupting mitochondrial respiratory chain, suppressing ATP production
Cyt‑c↑, and the release of Cyt c, destroy the electron transport chain, and impair mitochondrial function
MMPs↓, AgNPs can also inhibit the progression of tumors by inhibiting MMPs activity.
PI3K↓, Various studies support that AgNPs can deprive cancer cells of both nutrients and oxygen via inhibiting angiogenesis
Akt↓,
*Wound Healing↑, AgNPs exhibit good properties in promoting wound repair and bone healing, as well as inhibition of inflammation.
*Inflam↓,
*Bone Healing↑,
*glucose↓, blood glucose level of diabetic rats decreased when treated with AgNPs for 14 days and 21 days without significant acute toxicity.
*AntiDiabetic↑,
*BBB↑, The small-sized AgNPs are easy to penetrate the body and cross biological barriers like the blood-brain barrier and the blood-testis barrier
*eff↑, the addition of Ag+ to AA-AuNPs solution (pH 10) resulted in naked-eye color transitions from red to orange and yellow, with a blue shift in the absorption maximum from 522 to 400 nm
*other↝, The synthesis of AgNPs was primarily identified by the appearance of yellow colour and confirmed by showing λmax =409 nm in UV-visible spectroscopy.
*other↝, In this study, the bottom-up strategy was used to synthesize AgNPs using ascorbic
acid as a reductive agent and citric acid as a potent complex stabilizer, effectively.
*eff↑, It clearly explained that the reaction mixture having a pH at 10
is most appropriate to reduce Ag+ ions into AgNPs and stable over a month.
*eff↑, The FTIR results indicate that the citric acid is directly involved in the stabilization and capping of AgNPs, whereas ascorbic acid reduces Ag+ ions to Ag0.
Showing Research Papers: 1 to 50 of 1499
Page 1 of 30
Next
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1499
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
NA↑, 2,
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↓, 4, antiOx↑, 21, ARE/EpRE↑, 1, Catalase↓, 12, Catalase↑, 4, Catalase∅, 1, Copper↓, 1, CoQ10↑, 1, cystine↓, 1, DJ-1↓, 1, ENOX2↓, 2, ENOX2↑, 1, Fenton↑, 16, GCLM↓, 1, GPx↓, 8, GPx↑, 5, GPx1↓, 1, GPx1↑, 1, GPx4↓, 17, GSH↓, 79, GSH↑, 3, GSH↝, 1, GSH∅, 1, i-GSH∅, 1, mt-GSH↓, 1, GSH/GSSG↓, 12, GSR↓, 3, GSSG↓, 1, ox-GSSG↑, 1, GSTs↓, 2, GSTs↑, 2, GSTs∅, 1, H2O2?, 1, H2O2↑, 17, e-H2O2↓, 1, i-H2O2↑, 1, i-H2O2∅, 1, mt-H2O2↑, 1, HO-1↓, 8, HO-1↑, 14, HO-2↓, 1, HO-2↑, 1, hyperG↓, 1, Iron↓, 1, Iron↑, 12, Iron↝, 2, i-Iron↑, 2, c-Iron↑, 1, Keap1↓, 1, Keap1↑, 1, lipid-P?, 1, lipid-P↓, 4, lipid-P↑, 40, MDA↓, 3, MDA↑, 12, MPO↓, 1, NADH↑, 1, NADHdeh?, 1, NADPH/NADP+↓, 1, NQO1↓, 2, NQO1↑, 1, Nrf1↑, 2, NRF2↓, 18, NRF2↑, 21, NRF2↝, 3, p‑NRF2↑, 1, Prx↓, 1, Prx3↑, 1, Prx4↑, 1, Prx6↑, 2, PrxII↓, 1, PYCR1↓, 1, RNS↑, 2, ROS?, 6, ROS↓, 23, ROS↑, 568, ROS⇅, 7, ROS↝, 5, ROS∅, 1, i-ROS↓, 1, i-ROS↑, 6, mt-ROS↑, 18, RPM↑, 1, SOD↓, 18, SOD↑, 6, mt-SOD↑, 1, SOD1↓, 3, SOD1↑, 2, SOD2↓, 5, SOD2↑, 4, TAC↓, 3, Thiols↓, 3, i-Thiols↓, 1, Trx↓, 6, Trx↑, 1, Trx1↓, 1, ox-Trx1↑, 1, Trx2↓, 1, TrxR↓, 30, TrxR↑, 1, TrxR1↓, 10, TrxR1↑, 1, VitC↓, 1, VitE↓, 1, xCT/SLC7A11↓, 6, xCT/SLC7A11↑, 1,
Metal & Cofactor Biology(tgid=2) ⓘ
Ferritin↓, 5, Ferritin↑, 1, FTH1↓, 3, IronCh↑, 4, IRP1↑, 1, Mets↑, 1, NCOA4↑, 2, Tf↓, 1, TfR1/CD71↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
ADP:ATP↑, 1, CDC2↓, 3, CDC25↓, 10, CDC25↑, 2, compI↓, 7, compII↓, 1, compIII↓, 2, compIII↑, 1, compIV↓, 1, EGF↓, 1, ETC↓, 11, ETC↝, 1, HSP60/HSPD1↑, 1, Insulin↓, 4, MCU↓, 1, mitResp↓, 8, mitResp↑, 2, MKK7↓, 1, mtDam↑, 48, OCR↓, 13, OCR↑, 3, mt-OCR↓, 1, OXPHOS↓, 9, OXPHOS↑, 6, OXPHOS⇅, 1, OXPHOS↝, 3, mt-OXPHOS↑, 2, PDH↓, 4, PDH↑, 1, p‑PDH↓, 1, PGC-1α↑, 4, PINK1↑, 4, SDH↓, 4, SIRT3↓, 1, SIRT3↑, 1, TrxR2↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
12LOX?, 1, 12LOX↓, 3, 5LO↓, 4, ACC↓, 2, ACC↑, 1, p‑ACC↑, 1, ACLY↓, 7, p‑ACLY↓, 1, ACSL4↑, 2, adiP↑, 2, ADO↓, 1, Alanine↓, 1, ALAT↓, 2, ALAT∅, 1, ALDOA↓, 2, AMP↑, 1, AMPK↑, 25, AMPK↝, 1, p‑AMPK↑, 3, ATP↓, 44, ATP↑, 1, ATP∅, 1, i-ATP↓, 1, i-ATP↑, 1, Buty↑, 2, CAIX/CA9↓, 2, citrate↓, 1, CPT1A↓, 1, CRM↑, 1, CRM↝, 1, ECAR↓, 6, ECAR↝, 1, ENO1↓, 3, FABP4↓, 1, FAO↑, 1, FASN↓, 3, FASN↑, 2, FBPase↑, 1, GAPDH↓, 3, GLS↓, 1, glucoNG↑, 1, glucose↓, 2, glucose↑, 1, glucose∅, 1, GlucoseCon↓, 15, GlucoseCon↑, 2, GlucoseCon∅, 1, glut↓, 1, glyC↓, 1, Glycine↓, 1, Glycolysis↓, 53, Glycolysis↑, 3, Glycolysis↝, 1, GSK‐3β↓, 10, GSK‐3β↑, 4, p‑GSK‐3β↓, 4, p‑GSK‐3β↑, 1, Histones↑, 1, HK1↓, 1, HK2?, 1, HK2↓, 24, HK2↑, 1, HK2∅, 1, HMG-CoA↓, 3, KeyT↑, 1, lactateProd↓, 26, lactateProd↑, 4, lactateProd∅, 1, e-lactateProd↓, 1, LDHA↓, 12, LDHA↑, 1, LDHA∅, 1, LDL↓, 4, lipidLev↓, 1, lipidLev↑, 1, lipoGen↓, 1, MCT4↓, 1, NAD↓, 2, NADPH↓, 8, NADPH↑, 1, NH3↓, 1, PDK1 / PDPK1?, 2, PDK1 / PDPK1↓, 10, PDKs↓, 4, PFK↓, 6, PFK1↓, 2, PFK2?, 1, PFK2↓, 1, PFKP↓, 2, PGK1↓, 2, PGM1↓, 1, PGM1∅, 1, PKM2↓, 21, p‑PKM2↓, 1, polyA↓, 1, PPP↓, 2, PPP↑, 1, Pyruv↓, 1, SCD1↓, 3, SCFAs↑, 2, SIRT1↓, 9, SIRT1↑, 6, SREBP1/SREBF1↓, 2, SREBP2↓, 1, TCA?, 1, TCA↓, 2, TCA↑, 2, TCA↝, 1, TS↓, 3, UGDH↓, 2, Warburg↓, 11, Warburg↑, 1, β-oxidation↓, 1,
Cell Death(tgid=5) ⓘ
AIF↑, 19, APAF1↑, 6, Apoptosis?, 2, Apoptosis↓, 12, Apoptosis↑, 372, mt-Apoptosis↑, 6, ASC↓, 1, ASK1↑, 2, p‑ASK1↑, 1, aSmase↑, 1, BAD↓, 1, BAD↑, 10, Bak↓, 1, Bak↑, 11, BAX↓, 6, BAX↑, 152, Bax:Bcl2↑, 39, Bcl-2↓, 160, Bcl-2↑, 4, Bcl-2∅, 1, Bcl-xL↓, 39, Bcl-xL↑, 3, BID↓, 1, BID↑, 7, p‑BID↓, 1, cl‑BID↑, 2, BIM↑, 7, BNIP3?, 2, BNIP3↑, 1, BNIP3↝, 1, Casp↓, 1, Casp↑, 57, cl‑Casp↑, 1, Casp1↓, 1, Casp12?, 1, Casp12↑, 3, pro‑Casp12↓, 1, Casp2↑, 3, Casp3↓, 4, Casp3↑, 183, cl‑Casp3↑, 53, cl‑Casp3∅, 1, proCasp3↓, 3, proCasp3↑, 3, CASP4↑, 1, Casp6↑, 1, Casp7↑, 21, cl‑Casp7↑, 5, Casp8↓, 2, Casp8↑, 44, Casp8∅, 2, cl‑Casp8↑, 4, proCasp8↑, 2, Casp9↓, 1, Casp9↑, 109, cl‑Casp9↓, 1, cl‑Casp9↑, 21, proCasp9↓, 1, proCasp9↑, 2, CellShr↑, 1, cFLIP↓, 5, Cupro↑, 3, Cyt‑c↓, 1, Cyt‑c↑, 128, Cyt‑c↝, 1, Diablo↑, 5, DIDO1/DIO-1↑, 1, DR5↑, 23, Endon↑, 1, FADD↑, 6, Fap1↓, 1, Fas↓, 2, Fas↑, 17, FasL↓, 1, FasL↑, 14, FasL⇅, 1, Ferroptosis↓, 4, Ferroptosis↑, 31, GranB/GZMB↑, 1, GranB/GZMB↝, 1, GSDMD↑, 3, GSDME↑, 1, cl‑GSDME↑, 1, GSDME-N↑, 2, IAP1↓, 8, IAP2/BIRC3↓, 3, ICD↑, 5, iNOS↓, 10, iNOS↑, 1, Mcl-1↓, 24, p‑Mcl-1↓, 1, cl‑Mcl-1↑, 1, MDM2↓, 13, MDM2↑, 1, p‑MDM2↓, 1, MLKL↑, 3, p‑MLKL↓, 1, MOMP↓, 2, MOMP↑, 5, Necroptosis↑, 7, necrosis↑, 11, NOXA↑, 6, p38↓, 3, p38↑, 25, p‑p38↓, 1, p‑p38↑, 12, Paraptosis↑, 4, Perforin↑, 1, Perforin↝, 1, PUMA↑, 8, Pyro↑, 9, RIP3↑, 3, p‑RIP3↑, 2, SK↓, 1, survivin↓, 51, TRAIL↑, 5, TumCD↓, 4, TumCD↑, 56, TumCD∅, 2, TUNEL↑, 1, XIAP↓, 23, YAP/TEAD↓, 7, YAP/TEAD↑, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
ABL1↓, 1, Akt↓, 117, Akt↑, 6, p‑Akt↓, 40, p‑Akt↑, 4, AKT1↓, 2, AMPKα↑, 4, BRAF↓, 1, CaMKII
↓, 2, CaMKII
↑, 1, CK2↓, 2, cMET↓, 2, CREB↑, 1, cSrc↓, 1, DDIT4↑, 1, EGFR↓, 26, EGFR↑, 2, p‑EGFR↓, 1, ERK↓, 33, ERK↑, 12, p‑ERK↓, 12, p‑ERK↑, 9, e-ERK↑, 1, FOXD3↑, 1, GNAI1↓, 1, HCAR2↑, 1, HER2/EBBR2↓, 8, HGF/c-Met↓, 1, Hippo↓, 2, Hippo↝, 1, IGF-1R↓, 2, IGFR↓, 2, IKKα↓, 7, IKKα↑, 3, p‑IKKα↓, 1, IκB↑, 2, p‑IκB↓, 2, JAK↓, 2, JAK1?, 1, JAK1↓, 1, p‑JAK1↓, 1, JAK2↓, 9, p‑JAK2↓, 5, JNK↓, 6, JNK↑, 35, p‑JNK↑, 13, LATS1↓, 1, MAPK↓, 23, MAPK↑, 18, p‑MAPK↓, 1, p‑MAPK↑, 6, MEK↓, 2, p‑MEK↓, 2, p‑MEK↑, 1, MKK4↓, 1, MKP1↓, 1, MKP2↓, 1, Mst1↑, 1, mTOR↓, 61, mTOR↑, 3, mTOR⇅, 1, mTOR↝, 1, p‑mTOR↓, 13, mTORC2↓, 1, mTORC2↑, 1, p70S6↓, 2, P70S6K↓, 2, p‑P70S6K↓, 2, p85S6K↓, 1, p‑PDGFR-BB↓, 1, PI3K↓, 83, PI3K↑, 5, p‑PI3K↓, 5, PI3K/Akt↓, 1, PIK3CA↓, 1, PIK3CA↑, 1, PKA↓, 3, PKA↑, 1, PKCδ↓, 5, PTEN↓, 1, PTEN↑, 16, p‑PTEN↓, 1, Raf↓, 3, RAS↓, 5, RIP1↓, 2, RIP1↑, 2, p‑RSK↑, 1, p‑S6K↓, 1, Sp1/3/4↓, 7, Src↓, 2, p‑Src↓, 2, STAT↓, 4, STAT3↓, 58, STAT3↑, 3, STAT3⇅, 1, STAT3↝, 1, p‑STAT3↓, 15, p‑STAT3↑, 2, mt-STAT3↓, 1, STAT6↓, 2, p‑STAT6↓, 1, p‑STK11/LKB1↑, 1, TSC2↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
AntiThr↑, 1, ATF3↑, 1, ATF4↑, 10, ATF4↝, 1, CBP↓, 1, ChrMod↑, 1, cJun↓, 2, cJun↑, 3, p‑cJun↑, 1, cMyc↓, 31, cMyc↑, 1, DNMT1↓, 4, DNMT1↑, 1, DNMT3A↓, 1, DNMTs↓, 5, EZH2↓, 1, FOXO1↑, 2, FOXO3↓, 2, FOXO3↑, 5, FOXO4↑, 2, H3↓, 3, p‑H3↓, 1, p‑H3↑, 1, ac‑H3↓, 1, ac‑H3↑, 2, H3K27ac∅, 1, H4↓, 1, ac‑H4↓, 1, ac‑H4↑, 1, HATs↓, 1, HATs↑, 1, HDAC↓, 27, HDAC1↓, 4, HDAC10↓, 1, HDAC10↑, 1, HDAC2↓, 1, HDAC3↓, 2, HDAC8↓, 2, IRF1↑, 1, KLF2↓, 1, KLF5↓, 1, miR-124-3p↓, 1, miR-129-5p↑, 1, miR-133a-3p↑, 1, miR-139-5p↑, 1, miR-155↓, 1, miR-199↓, 1, miR-200b↑, 1, miR-200c↑, 1, miR-203↑, 1, miR-21↓, 1, miR-218↑, 1, miR-22↑, 1, miR-29b↑, 1, miR-30a-5p↑, 2, miR-375↑, 1, miR-490↑, 1, Myc↓, 5, n-MYC↓, 1, NDRG1↑, 1, OCT4↓, 10, other?, 4, other↓, 8, other↑, 18, other↝, 63, other∅, 2, PhotoS↑, 3, SD↑, 1, SETBP1↓, 1, sonoS↑, 2, SOX2↓, 7, SOX4↑, 1, SOX9↓, 1, SUV39H↓, 3, TCF-4↓, 1, TFE3↑, 2, tumCV?, 1, tumCV↓, 116, tumCV↑, 3, tumCV∅, 1,
Protein Folding & ER Stress(tgid=8) ⓘ
ATF6↑, 2, CHOP/DDIT3↓, 2, CHOP/DDIT3↑, 33, e-CRT↑, 1, EDEM↑, 1, eIF2α↓, 1, eIF2α↑, 6, p‑eIF2α↓, 1, p‑eIF2α↑, 8, ER Stress↓, 2, ER Stress↑, 81, ER Stress↝, 1, ERStress↑, 1, GRP78/BiP?, 1, GRP78/BiP↓, 5, GRP78/BiP↑, 18, HSF1↓, 1, HSP27↓, 1, HSP27↑, 1, HSP70/HSPA5↓, 6, HSP70/HSPA5↑, 4, e-HSP70/HSPA5↑, 1, HSP90↓, 14, HSP90↑, 2, e-HSP90↑, 2, ac‑HSP90↑, 1, HSPs↑, 2, HSPs∅, 1, IRE1↑, 4, NPL4↓, 2, PERK↑, 9, p‑PERK↓, 1, p‑PERK↑, 1, Proteasome↓, 4, PSMB5↓, 1, UPR↓, 1, UPR↑, 14, mt-UPR↑, 1, XBP-1↑, 6, XBP-1↝, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
APA↑, 1, ATG3↓, 1, ATG5↑, 5, ATG7↑, 1, Beclin-1/ATG6↓, 2, Beclin-1/ATG6↑, 14, p‑Beclin-1/ATG6↑, 1, LAMP1?, 1, LC3‑Ⅱ/LC3‑Ⅰ↑, 3, LC3B↑, 3, LC3B-II↑, 5, LC3II↑, 19, LC3s↑, 2, lysoMP↓, 1, lysoMP↑, 1, MitoP↑, 3, p62↓, 11, p62↑, 6, p‑p62↑, 1, PARK2↑, 4, SESN2↑, 3, TFEB↑, 1, TumAuto↓, 5, TumAuto↑, 76, TumAuto↝, 1, mt-TumAuto↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
ATM↓, 1, ATM↑, 5, ATR↑, 1, BRCA1↓, 2, p‑BRCA1↑, 1, BRCA2↓, 3, DNA-PK↑, 2, DNAdam↓, 5, DNAdam↑, 102, mt-DNAdam↑, 1, DNArepair↓, 4, hTERT/TERT↓, 8, MDMX↓, 1, NKX3.1↓, 2, p16↑, 3, P53↓, 6, P53↑, 75, P53↝, 3, P53∅, 1, p‑P53↑, 6, p53 Wildtype↓, 1, PARP↓, 6, PARP↑, 16, p‑PARP↑, 1, cl‑PARP↑, 105, cl‑PARP∅, 1, proPARP↓, 1, cl‑PARP1↑, 5, PCNA↓, 13, SIRT6↓, 2, SIRT6↑, 1, Telomerase↓, 16, TOP1↓, 4, TOP1↑, 1, TOP1↝, 1, TOP2↓, 2, TOP2↑, 2, TP53↓, 2, TRF2↓, 2, UHRF1↓, 1, γH2AX↑, 14, p‑γH2AX↑, 5,
Cell Cycle & Senescence(tgid=11) ⓘ
ANAPC2↑, 1, AURKB↑, 1, CDK1?, 1, CDK1↓, 12, p‑CDK1↓, 1, p‑CDK1↑, 1, CDK2↓, 22, CDK4↓, 32, CDK4↑, 3, p‑CDK4↓, 1, CDK6↓, 11, CDK6↑, 5, CDK8↓, 1, CDKN2C/p18↑, 1, cellSen↑, 1, CHK1↓, 1, Chk2↑, 2, Cyc↓, 2, cycA1/CCNA1↓, 8, cycA1/CCNA1↑, 2, CycB/CCNB1↓, 22, CycB/CCNB1↑, 5, cycD1/CCND1↓, 58, cycD1/CCND1↑, 1, p‑cycD1/CCND1↓, 1, CycD3↓, 2, CycD3↑, 1, cycE/CCNE↓, 14, cycE/CCNE↑, 1, cycF↑, 1, E2Fs↓, 1, GADD45A↑, 2, Ki-67↓, 28, mitA↓, 1, mitA↑, 1, p19↑, 1, P21↓, 3, P21↑, 61, p27/CDKN1B↑, 23, PLK1↓, 1, RB1↑, 2, p‑RB1↓, 4, TubPol↓, 1, TumCCA?, 1, TumCCA↓, 6, TumCCA↑, 241, UBE2C↓, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
ALDH↓, 9, ALDH1A1↓, 4, BMI1↓, 3, CD133↓, 9, CD24↓, 3, CD34↓, 1, cFos↓, 2, cFos↑, 1, cMYB↓, 1, CSCs↓, 48, CSCs↑, 2, CSCsMark↓, 1, Diff↓, 1, Diff↑, 4, FGF↓, 2, Gli↓, 1, Gli1↓, 6, HH↓, 8, HMGCR↓, 1, IGF-1?, 1, IGF-1↓, 18, IGF-1↑, 1, IGF-1↝, 1, IGF-1∅, 1, IGF-2↓, 1, IGFBP1↓, 1, IGFBP1↑, 3, IGFBP3↑, 3, Ki-67↓, 28, Let-7↑, 1, mTORC1↓, 4, p‑mTORC1↓, 1, Nanog↓, 10, Nestin↓, 1, NOTCH↓, 4, NOTCH↑, 1, NOTCH1↓, 5, NOTCH1↑, 1, NOTCH3↓, 1, p300↓, 1, Piezo1↑, 1, PTCH1↓, 2, Shh↓, 4, Smo↓, 4, STAT1↓, 2, TumCG?, 1, TumCG↓, 170, TumCG↑, 5, TumCG↝, 2, TumCG∅, 1, TumCP↓, 223, TumCP↑, 7, TumCP∅, 3, Wnt?, 1, Wnt↓, 28, Wnt/(β-catenin)↓, 2,
Migration(tgid=13) ⓘ
Alix/AIP‑1↓, 1, AntiAg↑, 2, AP-1↓, 7, ATPase↓, 1, ATPase↑, 1, AXL↓, 3, BACH1↑, 1, CA↓, 1, Ca+2↓, 8, Ca+2↑, 46, Ca+2↝, 5, i-Ca+2?, 1, i-Ca+2↓, 1, i-Ca+2↑, 3, CAFs/TAFs↓, 2, Cal9↑, 1, Cdc42↓, 2, Cdc42↑, 1, Chl↑, 1, Chl∅, 1, CTNNB1↓, 1, E-cadherin↓, 3, E-cadherin↑, 27, EMT↓, 49, EMT↑, 1, EpCAM↓, 1, F-actin↓, 1, FAK↓, 10, p‑FAK↓, 2, p‑FAK↑, 1, FOSB↑, 1, GLI2↓, 3, hnRNPA1↓, 1, ITGA1∅, 1, ITGA5∅, 1, ITGB1↓, 1, ITGB1∅, 1, ITGB3↓, 1, ITGB3∅, 1, ITGB4∅, 1, KRAS↓, 2, LEF1↓, 2, LRP1↓, 1, MALAT1↓, 1, MET↓, 2, p‑MET↓, 1, MMP1↓, 6, MMP13↓, 1, MMP2↓, 57, MMP2↑, 1, MMP2∅, 1, proMMP2↓, 1, MMP3↓, 3, MMP7↓, 4, MMP9↓, 66, MMP9↑, 2, MMP9∅, 1, MMPs↓, 20, MTA1↓, 1, MUC1↑, 1, N-cadherin↓, 10, N-cadherin↑, 1, NEDD9↓, 1, p‑p44↓, 1, PAK1↓, 3, PAK1↑, 1, PDGF↓, 3, Rac1↓, 1, Rho↓, 5, ROCK1↓, 2, Slug↓, 4, Smad1↓, 1, SMAD3↓, 2, Snail?, 1, Snail↓, 17, SPARC↑, 1, TET1?, 1, TET1↑, 2, TGF-β↓, 5, TGF-β1↓, 2, TIMP1↓, 1, TIMP1↑, 2, TIMP2↓, 1, TIMP2↑, 6, TRIB3↑, 1, TSC1↑, 1, TSP-1↑, 2, TumCA↓, 4, TumCA↑, 1, TumCI?, 1, TumCI↓, 65, TumCI↑, 1, TumCMig↓, 72, TumCMig↑, 2, TumMeta↓, 63, TumMeta↑, 5, TumPF↓, 1, Twist↓, 11, TXNIP↑, 1, Tyro3↓, 1, uPA↓, 9, uPAR↓, 2, Vim↓, 16, Vim↑, 1, Zeb1↓, 8, ZEB2↓, 1, α-tubulin↓, 1, β-catenin/ZEB1↓, 40, β-catenin/ZEB1↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 94, angioG↑, 4, angioG∅, 1, CD31/PECAM-1↓, 1, E-sel↓, 1, EGR1↑, 1, Endoglin↑, 1, eNOS↑, 1, HIF-1↓, 2, Hif1a↓, 49, Hif1a↑, 3, Hypoxia↓, 1, LOX1↓, 1, NO↓, 1, NO↑, 8, PHDs↓, 1, VCAM-1↓, 3, VEGF↓, 66, VEGFR1↓, 3, VEGFR2/KDR/Flk1↓, 5,
Barriers & Transport(tgid=15) ⓘ
AQPs↓, 2, BBB↑, 8, BBB∅, 1, CellMemb↓, 1, CellMemb↑, 6, CLDN1↓, 2, CLDN1↑, 1, CLDN2↓, 1, CLDN2↑, 1, CTR1↑, 1, EPR↓, 1, EPR↑, 21, EPR↝, 1, GLUT1↓, 16, GLUT1↑, 1, GLUT2↓, 1, GLUT3↓, 2, GLUT4↓, 3, IBI↑, 2, KCNH2/hERG↓, 1, LAT↓, 1, MMP?, 1, MMP↓, 205, MMP↑, 1, MPT↑, 11, NHE1↓, 2, OATPs↓, 1, OCLN↑, 1, SLC12A5↓, 2, SMCT1∅, 1, sonoP↑, 2, TJ↓, 1, TJ↑, 1, TRPM7↓, 2, TRPV1↑, 5, VGCC↑, 1, VGSC↑, 1, ZO-1↑, 4,
Immune & Inflammatory Signaling(tgid=16) ⓘ
CCR7↓, 1, CD14↓, 1, CD4+↓, 1, CD4+↑, 3, CD44↓, 12, CD47↓, 1, CD8+↑, 10, cDC2↓, 4, cGAS–STING↑, 1, COX1↓, 2, COX2/PTGS2↓, 50, COX2/PTGS2↑, 5, CR3↝, 1, CXCR2↓, 1, CXCR4↓, 11, DCells↑, 1, Dectin1↝, 1, DR4↑, 6, DR4∅, 1, DR6↑, 1, Eos↑, 1, Gal1↑, 1, HCAR2↑, 1, HMGB1↓, 2, e-HMGB1↑, 1, ICAM-1↓, 4, IFN-γ↓, 2, IFN-γ↑, 5, Igs↑, 2, IL-1Ra↑, 1, IL1↓, 3, IL1↑, 2, IL10↓, 4, IL10↑, 2, IL12↓, 1, IL12↑, 1, IL17↑, 1, IL18↑, 1, IL1R2↑, 1, IL1RL1/ST2↑, 1, IL1α↓, 1, IL1β↓, 12, IL1β↑, 1, IL2↓, 2, IL2↑, 6, IL4↓, 3, IL6↓, 28, IL6↑, 1, IL7↓, 1, IL8↓, 6, IL8↑, 1, Imm↑, 40, Imm↝, 3, Inflam↓, 34, Inflam↑, 1, IRAK4↓, 1, pol-M1↑, 1, pol-M1↝, 1, M2 MC↓, 3, pol-M2 MC↓, 1, MCP1/CCL2↓, 4, MIP-1β↑, 1, MIP2↓, 1, Neut↓, 1, NF-kB↓, 106, NF-kB↑, 5, p‑NF-kB↓, 1, p‑NF-kB↑, 1, NK cell↑, 15, NLRP3↓, 2, NLRP3↑, 3, p50↓, 1, p65↓, 7, p‑p65↓, 1, PD-1↓, 1, PD-L1↓, 12, PD-L1↑, 4, PDT+↓, 1, PGE2↓, 14, PSA↓, 14, RANTES↓, 2, SOCS1↑, 1, T-Cell↑, 3, T-Cell↝, 1, TCF↓, 3, TCF↝, 1, TLR1↑, 1, TLR2↓, 1, TLR4↓, 5, TNF-α↓, 20, TNF-α↑, 2, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1, TRAF1↓, 1,
Cellular Microenvironment(tgid=17) ⓘ
ADAM17↓, 1, GFAP↓, 1, pH↑, 7, pH↝, 2, pH∅, 1, e-pH↓, 1, e-pH↑, 6, i-pH↓, 1, TAMS↑, 1, Temp↓, 1,
Synaptic & Neurotransmission(tgid=18) ⓘ
5HT↓, 2,
Hormonal & Nuclear Receptors(tgid=20) ⓘ
2/16-OHE1↝, 1, 6IL↑, 1, ACTH↓, 1, AhR↓, 1, AR↓, 21, AR↑, 1, AR↝, 1, AR-FL↓, 1, AR-V7↑, 1, CYP11A1↓, 1, CYP19↓, 1, CYP24A1↓, 1, ER-α36↓, 1, ER(estro)↓, 2, Estro↝, 1, FKBP5↓, 1, GR↓, 1, Leptin↓, 1, PPARα↓, 1, PPARα↑, 1, PPARγ↓, 1, PPARγ↑, 4, RANKL↓, 1, SRC3↓, 1, SXR↑, 1, VDR↑, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 50, BioAv↑, 68, BioAv↝, 15, BioEnh?, 1, BioEnh↑, 10, CBR1↓, 1, chemoR↓, 2, ChemoSen?, 1, ChemoSen↓, 6, ChemoSen↑, 212, ChemoSen↝, 1, CompStab↓, 3, CompStab↑, 4, CompStab↝, 1, CYP1A1↓, 2, CYP1A1↑, 1, DDS↑, 10, Dose?, 18, Dose↓, 8, Dose↑, 22, Dose⇅, 1, Dose↝, 164, Dose∅, 29, DrugR↓, 1, eff?, 6, eff↓, 452, eff↑, 839, eff⇅, 4, eff↝, 153, eff∅, 26, GSTA1↓, 2, GSTZ1↓, 1, GSTZ1↝, 1, GSTZ1∅, 1, Half-Life↓, 17, Half-Life↑, 9, Half-Life↝, 13, Half-Life∅, 1, MDR1↓, 6, MRP↓, 2, MRP1/ABCC1↓, 1, MRP2↓, 1, P-gp/ABCB1↓, 21, P-gp/ABCB1∅, 1, P450↓, 2, RadioS↓, 1, RadioS↑, 83, RadioS↝, 1, RadioS∅, 1, selectivity?, 2, selectivity↓, 3, selectivity↑, 207, selectivity↝, 1, selectivity∅, 2, Synergy↑, 138, Synergy∅, 1, TET2↑, 3,
Clinical Biomarkers(tgid=22) ⓘ
AFP?, 1, AFP↓, 3, ALAT↓, 2, ALAT∅, 1, ALB∅, 1, ALP↓, 2, AR↓, 21, AR↑, 1, AR↝, 1, ascitic↓, 1, AST↓, 2, AST∅, 1, BG↓, 6, BMD↑, 2, BP↓, 1, BRAF↓, 1, BRCA1↓, 2, p‑BRCA1↑, 1, CA125↓, 1, CA125∅, 1, CA19-9↓, 1, CEA↓, 3, CRP↓, 2, CRP∅, 1, E6↓, 1, E7↓, 1, EGFR↓, 26, EGFR↑, 2, p‑EGFR↓, 1, EZH2↓, 1, Ferritin↓, 5, Ferritin↑, 1, Hcy/homoC↓, 4, Hcy/homoC↝, 1, HER2/EBBR2↓, 8, HOMA↓, 1, hTERT/TERT↓, 8, IL6↓, 28, IL6↑, 1, KeyT↑, 1, KRAS↓, 2, LDH?, 1, LDH↓, 8, LDH↑, 4, LDH↝, 1, i-LDH↓, 1, Myc↓, 5, NOS2↑, 1, NSE↓, 1, PD-L1↓, 12, PD-L1↑, 4, Polyps↓, 1, PSA↓, 14, TP53↓, 2, TRIB3↑, 1, Tumccf↓, 2,
Functional Outcomes(tgid=23) ⓘ
AntiAge↑, 2, AntiCan↓, 3, AntiCan↑, 84, AntiCan∅, 1, AntiDiabetic↑, 1, antiNeop↑, 4, AntiTum↓, 3, AntiTum↑, 36, AntiTum⇅, 1, cachexia↓, 2, cardioP↑, 10, CardioT↓, 1, CardioT↑, 2, CardioT↝, 1, chemoP↑, 42, chemoP↝, 1, chemoPv↑, 19, ChemoSideEff↓, 15, cognitive↑, 5, fatigue↓, 3, hepatoP↓, 1, hepatoP↑, 8, memory↑, 2, motorD↑, 1, Mucositis↓, 1, MusCon↓, 2, neuroP↑, 7, NKG2D↑, 1, NP/CIPN↓, 1, NP/CIPN↑, 2, OS?, 2, OS↑, 67, OS↝, 1, OS∅, 1, PARP16↓, 1, PFS?, 1, PFS↑, 3, QoL↑, 12, QoL∅, 3, radioP↑, 21, radioP↝, 1, Remission↑, 4, RenoP↑, 4, Risk↓, 39, Risk↑, 1, Risk∅, 4, Sleep↑, 1, Strength∅, 1, TGFβR1↓, 1, toxicity↓, 59, toxicity↑, 8, toxicity⇅, 1, toxicity↝, 26, toxicity∅, 7, TumNum↓, 1, TumVol↓, 61, TumW↓, 31, Weight↓, 1, Weight↑, 7, Weight∅, 5, Wound Healing↑, 2,
Infection & Microbiome(tgid=24) ⓘ
AntiP↑, 2, Bacteria↓, 4, Dectin1↝, 1, GutMicro↑, 14, GutMicro↝, 3, Sepsis↓, 1,
Ingredients & Constituents(tgid=25) ⓘ
Ingr?, 2, Ingr↝, 11,
Total Targets: 1261
Pathway results for Effect on Normal Cells:
NA, unassigned(tgid=0) ⓘ
NA↑, 2,
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx?, 1, antiOx↓, 10, antiOx↑, 111, mt-antiOx↑, 1, ARE↑, 2, Bil↓, 1, Catalase↓, 1, Catalase↑, 38, Copper↓, 1, CoQ10↑, 1, DPPH↓, 1, Fenton↓, 3, GPx↑, 28, GPx1↑, 1, GPx4↓, 1, GPx4↑, 3, GPx4∅, 1, GSH↓, 3, GSH↑, 50, GSR↑, 4, GSTs↑, 9, H2O2↓, 5, H2O2↑, 1, HDL↓, 1, HDL↑, 5, HDL∅, 2, HO-1?, 1, HO-1↓, 1, HO-1↑, 29, HO-1↝, 1, HO-1∅, 1, hyperG↓, 2, Iron↓, 3, Iron↑, 1, Keap1↓, 2, Keap1↑, 1, lipid-P↓, 33, lipid-P↑, 1, mt-lipid-P↓, 1, MDA↓, 31, MDA↑, 1, MDA∅, 1, MPO↓, 7, MPO↑, 1, NADH↓, 1, NOX↓, 1, NOX4↓, 1, NQO1↑, 9, Nrf1↑, 1, NRF2↓, 4, NRF2↑, 56, NRF2⇅, 1, NRF2∅, 1, Prx↑, 1, RNS↓, 5, ROS?, 4, ROS↓, 141, ROS↑, 15, ROS⇅, 4, ROS↝, 1, ROS∅, 7, mt-ROS↓, 1, mt-ROS↑, 2, selenoP↑, 4, SOD↓, 3, SOD↑, 60, SOD1↑, 2, TAC↑, 7, TBARS↓, 4, Trx↑, 2, TrxR↑, 1, uricA↓, 3, VitC↑, 4, VitE↓, 1, VitE↑, 1, xCT/SLC7A11↑, 1,
Metal & Cofactor Biology(tgid=2) ⓘ
Ferritin↓, 1, FPN↑, 1, IronCh↑, 6, IronCh↝, 1, Mets↝, 1, NCOA4↝, 1, selm↑, 1, TfR1/CD71↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
compI↓, 1, compII↑, 1, compIII↓, 1, compIII↑, 1, DRP1/DNM1L↑, 1, ETC↓, 1, ETC↑, 1, FIS1↓, 1, FIS1↑, 1, Insulin↓, 3, Insulin↑, 1, mitResp↑, 2, mtDam↓, 6, OCR↑, 1, mt-OCR↑, 1, OXPHOS↑, 1, PGC-1α↑, 4,
Core Metabolism/Glycolysis(tgid=4) ⓘ
12-HETE↓, 1, 12LOX↓, 3, 5-HETE↓, 1, 5LO↓, 3, ACSL4∅, 1, adiP↓, 1, adiP↑, 2, ALAT↓, 15, ALAT∅, 1, AMPK↓, 1, AMPK↑, 6, ATP↓, 3, ATP↑, 9, BHB↑, 1, cAMP↑, 2, DHA↑, 1, ECAR↓, 1, ECAR↑, 1, Eic↓, 1, mt-FAO↑, 1, glucose↓, 4, glucose↑, 1, GlucoseCon↑, 4, Glycolysis↓, 1, GSK‐3β↓, 4, GSK‐3β↑, 1, GSK‐3β↝, 1, p‑GSK‐3β↑, 1, KeyT↑, 4, lactateProd↓, 1, LDL↓, 15, lipidLev↓, 1, NAD↑, 1, NADH:NAD↑, 1, NADPH↓, 2, NADPH↑, 3, PKM2↓, 2, SCD1↓, 1, SIRT1↓, 1, SIRT1↑, 9, SIRT2↑, 1,
Cell Death(tgid=5) ⓘ
Apoptosis↓, 18, Apoptosis↑, 1, Apoptosis∅, 2, ASK1↓, 1, BAX↓, 7, BAX↑, 2, Bax:Bcl2↓, 2, Bcl-2↓, 2, Bcl-2↑, 4, Bcl-2∅, 1, Bcl-xL↓, 1, Bcl-xL↑, 1, Casp12↓, 2, Casp3↓, 17, Casp3↑, 2, Casp3∅, 1, cl‑Casp3↓, 2, Casp8↓, 1, cl‑Casp8↑, 1, Casp9↓, 6, Casp9↑, 1, Cyt‑c↓, 5, Cyt‑c↑, 3, Cyt‑c∅, 3, Ferroptosis↓, 4, GranB/GZMB↓, 1, HEY1↑, 1, iNOS↓, 14, iNOS↑, 1, necrosis↓, 1, p38↓, 1, p38↑, 2, p‑p38↓, 1, TUNEL↓, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
Akt↓, 4, Akt↑, 7, e-Akt↑, 1, AKT1↓, 1, Akt2↓, 1, AMPKα↑, 1, CREB↑, 1, ERK↓, 1, ERK↑, 4, e-ERK↑, 1, HCAR2↑, 1, IKKα↓, 1, IκB?, 1, JAK2↑, 1, JNK↓, 4, JNK↑, 1, p‑JNK↓, 1, MAPK↓, 7, MAPK↑, 7, Mst1↓, 1, mTOR↓, 5, mTOR↑, 1, mTOR↝, 1, p‑mTOR↓, 1, p‑mTOR↑, 1, PI3K↓, 4, PI3K↑, 4, PKA↑, 2, PKCδ?, 1, PKCδ↓, 1, PKCδ↑, 1, PP2A↑, 1, PTEN↓, 2, RAS↓, 1, STAT↓, 1, STAT3↓, 3, STAT3↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
AntiThr↑, 4, ATF4↓, 1, FOXO↑, 1, HDAC?, 1, HDAC↓, 1, other?, 4, other↓, 9, other↑, 30, other↝, 48, SOX9↑, 1, tumCV↓, 1, tumCV∅, 1,
Protein Folding & ER Stress(tgid=8) ⓘ
CHOP/DDIT3↓, 2, CHOP/DDIT3↑, 1, p‑eIF2α↓, 1, cl‑eIF2α↑, 1, ER Stress↓, 7, ER Stress↑, 1, GRP78/BiP↓, 4, GRP78/BiP↑, 1, HSF1↑, 2, HSP70/HSPA5↓, 1, HSP70/HSPA5↑, 3, HSP70/HSPA5↝, 1, HSPs↑, 3, IRE1↓, 2, p‑PERK↑, 1, UPR↓, 1, XBP-1↓, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
CTSZ↓, 1, LC3‑Ⅱ/LC3‑Ⅰ↑, 1, LC3II↑, 1, MitoP↑, 1, p62↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
8-oxo-dG↓, 1, DNAdam↓, 13, DNAdam↑, 2, DNArepair↑, 3, P53↑, 2, PARP↓, 1, γH2AX↓, 1, p‑γH2AX↓, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
cycD1/CCND1↓, 1, E2Fs↑, 1, P21↑, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
BMP2↑, 1, CHIP↑, 1, Choline↑, 1, Diff↑, 4, Diff↝, 1, FGF↑, 1, IGF-1↓, 2, IGFBP3↑, 1, neuroG↑, 1, NOTCH↑, 1, TumCP↓, 3, tyrosinase↓, 1, Wnt↑, 2,
Migration(tgid=13) ⓘ
AntiAg↓, 1, AntiAg↑, 14, ARG1/2↑, 1, Ca+2↓, 3, Ca+2↑, 7, Ca+2↝, 4, cal2↓, 1, Cartilage↑, 1, COL1↓, 1, COL2A1↑, 1, E-cadherin↑, 1, EMT↓, 2, EMT↑, 1, F-actin↑, 1, FAK↑, 2, MLC2/MYL9↝, 1, MMP13↓, 1, MMP2↓, 2, MMP2↑, 2, MMP9↓, 11, MMP9↑, 2, MMPs↓, 1, MMPs↑, 1, PAI-1/SERPINE1↓, 1, SMAD3↓, 2, Snail↑, 1, TG2/TGase↓, 1, TGF-β↓, 1, TGF-β↑, 4, TGF-β1↓, 1, TIMP1↓, 2, TIMP1↑, 1, TumCI↓, 1, TumCMig↓, 1, Twist↑, 1, Vim↓, 1, Vim↑, 1, α-SMA↓, 1, β-catenin/ZEB1↑, 2,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 1, angioG↑, 2, CD31/PECAM-1↑, 1, eNOS↑, 1, Hif1a↓, 2, Hif1a↑, 2, Hif1a∅, 1, NO?, 1, NO↓, 14, NO↑, 4, TXA2↓, 1, VCAM-1↓, 2, VEGF↓, 2, VEGF↑, 5,
Barriers & Transport(tgid=15) ⓘ
AQPs↓, 1, BBB↓, 1, BBB↑, 38, BBB↝, 1, BBB∅, 2, CellMemb↑, 1, CLDN1↓, 1, CLDN1↑, 2, CLDN1↝, 1, EPR↑, 1, GastroP↑, 5, GLUT1↑, 2, GLUT3↑, 1, GLUT4↑, 1, IBI↑, 3, ketosis↑, 1, MMP↓, 4, MMP↑, 10, MMP↝, 1, MMP∅, 2, MPT↑, 1, OCLN↑, 1, OCLN↝, 1, TJ↓, 1, TJ↑, 2, TRPV3↑, 1, VGCC↑, 2, VGCC⇅, 1, VGSC↓, 1, ZO-1↓, 1, ZO-1↑, 3, ZO-1↝, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
CD14↑, 1, CD25+↑, 1, CD4+↑, 3, CD40↓, 1, CD8+↑, 2, COX1↓, 4, COX2/PTGS2↓, 22, CXCR4↓, 1, DEFB1↑, 1, Eos↓, 1, FOXP3↑, 1, HCAR2↑, 1, HMGB1↓, 2, IFN-γ↓, 3, IFN-γ↑, 3, IgE↓, 1, IL1↓, 3, IL10?, 1, IL10↓, 3, IL10↑, 9, IL10∅, 1, IL13↑, 1, IL17↓, 7, IL17∅, 1, IL18↓, 1, IL1α↓, 1, IL1β↓, 27, IL2↓, 2, IL22↓, 1, IL23↓, 1, IL4↓, 1, IL4↑, 3, IL4∅, 1, IL5↑, 1, IL6?, 1, IL6↓, 34, IL6↑, 4, IL8?, 1, IL8↓, 3, Imm↑, 19, Imm⇅, 1, INF-γ↓, 1, Inflam?, 1, Inflam↓, 143, Inflam↑, 2, IP-10/CXCL-10↓, 1, IRF3↓, 1, LPS↓, 2, M2 MC↑, 1, MCP1/CCL2↓, 4, MCP1/CCL2↑, 1, MIP‑1α/CCL3↓, 1, MyD88↓, 2, NeuroI↓, 2, NF-kB↓, 32, NF-kB↑, 3, NK cell↑, 1, NLRP3↓, 5, NLRP3↑, 1, p65↓, 1, PAF↓, 1, PGE2↓, 9, PSA↓, 1, TLR1↓, 1, TLR2↓, 2, TLR4↓, 4, TNF-α↓, 50, TNF-α↑, 2, Treg lymp↑, 1, Treg lymp↝, 1,
Cellular Microenvironment(tgid=17) ⓘ
pH↝, 1, Temp↝, 1,
Synaptic & Neurotransmission(tgid=18) ⓘ
5-AR↓, 2, 5HT↓, 1, 5HT↑, 2, Ach?, 1, Ach↑, 6, AChE↓, 25, AChE∅, 2, ADAM10↑, 1, BChE↓, 10, BDNF↑, 16, BrainVol↑, 1, BrainVol∅, 1, ChAT↑, 1, GABA↑, 4, MAOA↓, 2, NMDAR↑, 1, PSD95↑, 1, SNAP25↑, 1, TrkB↑, 1, β-Endo↑, 1,
Protein Aggregation(tgid=19) ⓘ
AGEs↓, 3, APP↓, 4, Aβ↓, 32, Aβ42↓, 1, BACE/β-secretase↓, 9, IDE↑, 1, tau↓, 5, p‑tau↓, 8, XO↝, 1, β-Amyloid↓, 1,
Hormonal & Nuclear Receptors(tgid=20) ⓘ
AR↓, 1, BNP↓, 1, GPER↑, 1, GR↑, 2, PPARα↑, 1, PPARγ↓, 1, PPARγ↑, 3,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv?, 1, BioAv↓, 36, BioAv↑, 73, BioAv⇅, 1, BioAv↝, 26, BioAv∅, 1, BioEnh↑, 8, ChemoSen↑, 1, CompStab↓, 1, CompStab↑, 5, CompStab↝, 2, CYP1A1↓, 1, CYP2C19↓, 1, CYP2C8↓, 1, CYP2C9↓, 1, CYP2D6↓, 1, CYP2E1↓, 1, CYP3A4↓, 2, DDS↑, 1, Dose?, 7, Dose↓, 8, Dose↑, 7, Dose⇅, 1, Dose↝, 102, Dose∅, 2, eff?, 3, eff↓, 39, eff↑, 299, eff↝, 41, eff∅, 4, GSTA1↓, 2, GSTA1↑, 1, GSTP1/GSTπ↑, 1, Half-Life↓, 5, Half-Life↑, 8, Half-Life⇅, 1, Half-Life↝, 15, Half-Life∅, 4, P-gp/ABCB1↓, 3, P450↓, 1, selectivity↑, 2, Synergy↑, 14,
Clinical Biomarkers(tgid=22) ⓘ
ALAT↓, 15, ALAT∅, 1, ALP↓, 4, ALP↑, 1, anemia↓, 1, AR↓, 1, AST↓, 15, AST∅, 1, BG↓, 2, Bil↓, 1, BloodF↑, 4, BMD↑, 7, BP↓, 16, BP∅, 1, BUN↓, 3, colonLen↑, 1, creat↓, 6, CRP↓, 8, Ferritin↓, 1, FEV1↑, 2, Hcy/homoC↓, 2, HemoG↑, 1, hs-CRP↓, 1, IL6?, 1, IL6↓, 34, IL6↑, 4, KeyT↑, 4, LDH↓, 6, LDH↑, 1, LDH∅, 1, NLR↓, 1, NOS2↓, 2, PEF↑, 1, PSA↓, 1, PV↓, 1, RBC↑, 1, SpO2↑, 1, TC↓, 2, TG/TAG↓, 1, TMAO↑, 3, TMAO⇅, 1, UFR?, 1, UFR↑, 1, UR↓, 1, Urea↓, 1,
Functional Outcomes(tgid=23) ⓘ
Analgesic↑, 1, AntiAge↑, 6, antiAll↑, 17, antiAll∅, 1, AntiArt↑, 7, AntiCan↑, 13, antiD↓, 1, AntiDiabetic↑, 21, antiPs↑, 1, AntiTum↓, 1, AntiTum↑, 5, ANXi↓, 1, BOLD↑, 2, Bone Healing↑, 1, cachexia↓, 1, cardioP↑, 40, CardioT↓, 3, chemoP↑, 11, chemoPv↑, 5, cognitive?, 1, cognitive↓, 3, cognitive↑, 76, cognitive∅, 1, diuretic↑, 1, fatigue↓, 1, hepatoP↓, 1, hepatoP↑, 34, IPSS↝, 1, Learn↑, 1, memory↓, 2, memory↑, 42, memory∅, 1, Mood?, 1, Mood↑, 5, motorD↓, 1, motorD↑, 13, MusCon↓, 1, Nausea↓, 1, neuroP?, 1, neuroP↑, 75, Obesity↓, 11, OS↓, 1, OS↑, 5, Pain↓, 9, PDE4↓, 1, QoL↓, 1, QoL↑, 1, radioP↑, 4, RenoP↑, 15, Risk↓, 9, Risk↑, 2, Sleep↑, 6, Strength↑, 2, Stress↓, 4, Stroke↓, 8, toxicity?, 3, toxicity↓, 83, toxicity↑, 7, toxicity↝, 15, toxicity∅, 27, Vomit↓, 1, Weight↓, 4, Weight↑, 1, Weight↝, 1, Weight∅, 1, Wound Healing↓, 1, Wound Healing↑, 11,
Infection & Microbiome(tgid=24) ⓘ
AntiBio↑, 13, AntiFungal↑, 4, AntiP↓, 1, AntiP↑, 2, AntiViral↑, 14, Bacteria↓, 29, Diar↓, 1, Dysb↓, 1, GutMicro↑, 18, GutMicro↝, 1, GutMicro∅, 1, Inf↓, 2, Sepsis↓, 7,
Ingredients & Constituents(tgid=25) ⓘ
Ingr?, 1, Ingr↑, 6, Ingr↝, 19, Phen?, 1, Phen↑, 1, Poly↑, 2,
Total Targets: 640
Scientific Paper Hit Count for: eff, efficacy
66
Silver-NanoParticles59
Magnetic Fields34
Sulforaphane (mainly Broccoli)28
Thymoquinone27
Curcumin26
immunotherapy26
Shikonin25
Chemotherapy25
Vitamin C (Ascorbic Acid)23
chitosan22
Selenite (Sodium)21
Radiotherapy/Radiation21
Baicalein21
Selenium NanoParticles20
Piperlongumine19
Copper and Cu NanoParticles19
EGCG (Epigallocatechin Gallate)19
Magnetic Field Rotating18
Artemisinin16
Melatonin16
Berberine16
Exercise15
Chlorogenic acid14
Apigenin (mainly Parsley)14
Luteolin14
Phenylbutyrate14
Caffeic acid14
Capsaicin14
Resveratrol14
Quercetin14
Gambogic Acid13
Phenethyl isothiocyanate13
Selenium13
diet FMD Fasting Mimicking Diet12
Gold NanoParticles12
Citric Acid12
Ashwagandha(Withaferin A)12
Propolis -bee glue12
Folic Acid, Vit B912
Dichloroacetate12
Hydrogen Gas11
3-bromopyruvate11
Benzyl isothiocyanate11
Cisplatin11
Betulinic acid11
Ivermectin11
Lycopene10
Vitamin D310
Choline10
diet Methionine-Restricted Diet10
Disulfiram10
Honokiol9
Auranofin9
Metformin9
borneol9
doxorubicin9
Electrical Pulses9
Formononetin9
Bicarbonate(Sodium)8
Photodynamic Therapy8
Fenbendazole8
SonoDynamic Therapy UltraSound8
chaetocin8
Diindolylmethane8
Fisetin8
Hyperthermia8
Plumbagin8
Rosmarinic acid7
Coenzyme Q107
Allyl isothiocyanate7
Docetaxel7
Boron7
buckwheat sprouts7
Ellagic acid7
Chrysin7
Dandelion Root7
Juglone7
VitK3,menadione7
Mung Bean Sprouts7
mebendazole7
salinomycin6
Alpha-Lipoic-Acid6
beta-glucans6
isoorientin6
Carnosic acid6
Celastrol6
Vitamin B126
Chlorophyllin6
Docosahexaenoic Acid6
Eugenol6
MCT oil6
Flaxseed/Linseed6
Ginger/6-Shogaol/Gingerol6
isoquercitrin6
MCT, metronomic chemo6
Moringa oleifera6
Parthenolide6
Vitamin K25
Astragalus5
Akkermansia5
Bevacizumab (brand Avastin)5
Ascorbyl Palmitate5
Lutein5
Bifidobacterium5
Boswellia (frankincense)5
Piperine5
Silymarin (Milk Thistle) silibinin5
Cynaropicrin5
Diclofenac5
eicosapentaenoic acid5
diet Plant based5
Lemongrass Extract/Citral5
Ginkgo biloba-EGb 7615
Gossypol/AT-1015
Isoliquiritigenin5
Licochalcone A5
Nimbolide5
Spermidine5
Urolithin4
chemodynamic therapy4
EMF4
Cynara scolymus/Globe Artichoke/Artichoke Extract4
Allicin (mainly Garlic)4
almonertinib4
Berbamine4
Black Rice, Oryza sativa4
α-Bisabolol / Chamomile oil4
Butyrate4
capecitabine4
Carvacrol4
Cat’s Claw4
Centella asiatica / Gotu kola → asiaticoside4
CUSP94
diet Short Term Fasting4
Echinacea4
Kaempferol4
phytic acid, Inositol hexakisphosphate4
Fucoidan4
Ginkgolide B4
Ginseng4
HydroxyCitric Acid4
Magnolol4
Isobavachalcone4
Matrine4
methylseleninic acid4
Methylsulfonylmethane4
Propyl gallate4
Phycocyanin4
Pterostilbene4
Terpinen-4-ol / Tea Tree Oil4
Whole Body Vibration3
cetuximab3
5-fluorouracil3
Açaí, Euterpe oleracea3
Anthocyanins3
Aspirin3
Atorvastatin3
Aloe anthraquinones3
bempedoic acid3
beta-carotene(VitA)3
Zeaxanthin3
Bortezomib3
Bullatacin3
NTP, Non-Thermal Plasma,Cold Atmospheric Plasma3
Thymol-Thymus vulgaris3
Cannabidiol3
Chocolate3
Cichoric acid / Chicoric acid3
Crocetin3
Cysteamine3
erastin3
Gallic acid3
Gamma-aminobutyric acid3
Ginkgo biloba3
Lemon Balm/Melissa officinalis3
Germanium Organic/Ge-132 / propagermanium (organogermanium)3
Gemcitabine (Gemzar)3
Hibiscus sabdariffa3
HydroxyTyrosol3
iodine3
Inulin Prebiotic3
isoflavones3
Licorice3
Lactoferrin/Talactoferrin3
Moringin3
Mushroom Lion’s Mane, Hericium erinaceus3
Mushroom Maitake3
nicotinamide adenine dinucleotide3
Patchouli Oil (Pogostemon cablin)3
Radio Frequency3
Sulfasalazine3
Taurine3
Vitamin B1/Thiamine3
Walnut2
1,8-Cineole2
2-DeoxyGlucose2
Glucose2
Zinc2
Andrographis2
Anti-oxidants2
Vitamin A, Retinoic Acid2
Aromatherapy2
Astaxanthin2
Arsenic trioxide2
Baicalin2
Huperzine A/Huperzia serrata2
Beta-Caryophyllene2
Bufalin/Huachansu2
temozolomide2
probiotics2
Nasturtium, Indian Cress2
brusatol2
Black turtle bean2
Vitexin2
Isovitexin2
Rutin2
Caffeic Acid Phenethyl Ester (CAPE)2
Caffeine2
Calcium2
Camu camu2
Celecoxib2
Hydroxycinnamic-acid2
Citicoline, CDP-Choline2
Cranberry2
Calorie Restriction Mimetics2
Cyclopamine2
Dichloroacetophenone(2,2-)2
Deguelin2
Date Fruit Extract2
diet Ketogenic2
Oxygen, Hyperbaric2
D-limonene2
statins2
Emodin2
Vitamin E2
ferumoxytol2
Paclitaxel/Taxol2
SDG/lignans2
tamoxifen2
Garcinol2
Geldanamycin2
γ-linolenic acid (Borage Oil)2
Grapeseed extract2
Orlistat2
hydroxychloroquine2
Helleborus niger extracts – Christmas Rose2
Hyperoside2
Isothiocyanates2
itraconazole2
Potassium2
L-Theanine2
lambertianic acid2
Lapachol2
Methylene blue2
Methyl Jasmonate2
Magnesium2
Mistletoe/Viscum album Extracts2
Naringin2
Marjoram (Origanum majorana)2
Purple Corn / Purple Maize2
Rauwolfia serpentina/Indian Snakeroot2
Spirulina(Arthrospira/Limnospira)2
Aflavin-3,3′-digallate2
tetrathiomolybdate2
Ursolic acid1
5-Aminolevulinic acid1
Anzaroot, Astragalus fasciculifolius Bioss1
wortmannin1
Resiquimod1
Aidi injection1
Acetyl-l-carnitine1
Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry1
Amodiaquine1
DTS(dibenzyl trisulphide) from Anamu1
Anethole/trans-Anethole1
Fennel Oil/Foeniculum vulgare1
Sorafenib (brand name Nexavar)1
Trastuzumab1
Biochanin A1
Brucea javanica1
Bacopa monnieri1
Bromelain1
Bruteridin(bergamot juice)1
urea1
Cannabichromene1
Beta‐Lapachone1
Cimetidine1
Cinnamon1
Carica papaya leaf extract1
Camptothecin1
irinotecan1
Carvone1
Polyphenols1
Black phosphorus1
Cucurbitacin1
Chlorella (Chlorella vulgaris)1
gefitinib, erlotinib1
Dasatinib/Phyrago1
Dihydrocaffeic Acid1
diet Fermented Foods1
Ormeloxifene (Centchroman)1
Dipyridamole1
Protocatechuic acid1
PXD, phenoxodiol1
Eurycomanone1
flavonoids1
Flickering Light Stimulation1
Flaxseed Oil1
Galloflavin1
verapamil1
Salvia officinalis1
Germanium inorganic1
Geraniol1
Germanium-Spirogermanium1
Ginkgetin1
Glabrescione B1
Graviola1
High-Ozonide Oil1
Indole-3-carbinol1
entinostat1
Recombinant Methioninase1
Lactobacillus1
Laetrile B17 Amygdalin1
Lapatinib1
low dose naltrexone1
Lecithin1
Linalool1
Modified Citrus Pectin1
carboplatin1
Mangiferin1
Methylglyoxal1
magnetic nanoparticles1
Morin1
Mucuna pruriens/Velvet Bean1
Mushroom Chaga, Inonotus obliquus1
Mushroom Reishi1
Myricetin1
No Product/Mechanism Only1
Oleocanthal1
Peppermint1
sericin1
Phosphatidylserine1
Pumpkin Seed Oil / Cucurbita pepo1
Tamsulosin1
enzalutamide1
Rhein1
Oxaliplatin1
α-Santalol/Sandalwood oil1
Scoulerine1
polyethylene glycol1
Iron1
Squalene1
Glutathione1
Sutherlandioside D1
triptolide1
Triphala1
Tumor Treating Fields1
Turmerones1
Vitamin B3,Niacin1
Vitamin B5,Pantothenic Acid1
Vitamin B6,pyridoxine1
Wogonin1
Zyflamend
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=on sortOrder:rid,rpid
Home Page